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The most effective therapy for patients with unexplained RPL is often the most 
simple: antenatal counseling and psychological support. 
    Holly B Ford, 2009 
 
  
 
  
 
  
 
Abstract 
 
 
Background/Aims: Recurrent pregnancy loss (RPL) occurs in 1-2% of fertile 
couples and about 50% of cases are unexplained. Impaired placental circulation, 
increased platelet aggregation, immunological factors and thyroid autoimmunity 
have been suggested to be involved. Other placenta-mediated complications have 
been reduced by inhibition of platelet aggregation with acetylsalicylic acid (ASA). 
The effect of ASA on RPL has been unclear. These studies aimed at investigating 
the effect of ASA treatment on RPL and arachidonic acid (AA)-induced platelet 
aggregation in women with RPL, as well as the effect of thyroid function by 
analyzing Thyroid Stimulating Hormone (TSH) and thyroid peroxidase antibodies 
(TPO-ab). 
 
Methods: Women (n=640) with at least three unexplained first-trimester 
miscarriages were screened for inclusion in a single-center, randomized, placebo-
controlled trial (the ASA-RCT, Paper I). Four hundred women were given either 75 
mg ASA or placebo daily, beginning at gestational week (gw) 6-7, when fetal 
heartbeat was detected by vaginal ultrasound. Treatment ended at the latest at gw 36. 
Treatment compliance was determined by analysis of AA-induced platelet 
aggregation using multiple electrode impedance aggregometry. All women 
underwent the same follow-up. Primary outcome was live birth rate (LBR). 
 
In order to define reference values for the multiple electrode impedance 
aggregometry (the Multiplate analyzer), a longitudinal study was conducted 
including 79 healthy, non-smoking pregnant women with normal pregnancies (Paper 
II). Platelet aggregation induced by AA, adenosine diphosphate (ADP), thrombin 
receptor activating peptide 6 (TRAP) and collagen (COL) were determined four 
times during pregnancy and three months postpartum. 
 
From the randomized population, 176 and 177 women, respectively, with normal 
AA-induced platelet aggregation before pregnancy and treated with ASA or placebo, 
were studied (Paper III). Platelet aggregation was determined before and during 
pregnancy and results in the randomized groups were compared with one another, as 
well as with those in the healthy controls from Paper II.  
 
  
 
From the screened and eligible population, 495 women with complete thyroid test 
analyses [thyroid stimulating hormone (TSH), free thyroxine (T4) and thyroid 
peroxidase antibodies TPO-ab] before pregnancy were included. Risk factors for a 
new miscarriage were studied, in particular associations with TPO-ab and TSH in 
the upper normal range. 
 
Results: In the ASA-RCT, all 400 randomized women completed the follow-up. 
LBR were 83.0% and 85.5% in the ASA and placebo groups, respectively. The mean 
difference was -2.5% (95% CI to -10.1% to 5.1%). The risk ratio was 0.97 (95% CI  
0.89 to 1.06). 
 
In the longitudinal study of platelet aggregation during normal pregnancy, activation 
of platelets by AA, ADP and TRAP resulted in a minor decrease in platelet 
aggregation during pregnancy, compared with postpartum. COL-induced platelet 
aggregation was unchanged. A minor increase in platelet aggregation as pregnancy 
continued was found related to ADP. 
 
There were no significant differences in AA-induced platelet aggregation when 
placebo-treated women with RPL were compared with healthy women with normal 
pregnancies. ASA treatment significantly reduced platelet aggregation during 
pregnancy, compared with before pregnancy. Gradually increased platelet 
aggregation was seen in the majority of ASA-treated women as pregnancy 
progressed. There were only two complete non-responders to ASA. 
 
Miscarriage occurred more often in women with than without TPO-ab (25.7% vs 
17.5%). There was no association between TSH in the upper normal range and a new 
miscarriage. Independent risk factors for a new miscarriage were age, number of 
previous miscarriages and presence of TPO-ab. 
 
Conclusions: ASA does not prevent a new miscarriage in women with at least three 
previous first-trimester miscarriages. AA-induced platelet aggregation seems to be 
similar in women with RPL and in healthy women with normal pregnancies. ASA, 
75 mg daily, decreases AA-induced platelet aggregation in most women during 
pregnancy, but the effect diminishes as pregnancy progresses. TPO-ab, but not TSH 
in the upper normal range, may be associated with an increased risk of a new 
miscarriage. 
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Populärvetenskaplig sammanfattning 
 
 
Bakgrund 
 
Upprepade missfall drabbar omkring 1 på 100 av fertila par varav ungefär hälften 
inte har en påvisbar trolig orsak. Upprepade missfall i tidig graviditet kan definieras 
på olika sätt utifrån antal tidigare missfall och när i graviditeten de inträffat. I 
avhandlingens studier, har kvinnorna minst tre oförklarade missfall i följd under 
graviditetens första tredjedel och dessa tillsammans med samma partner. 
 
Kvinnans ålder och antal tidigare missfall har i tidigare studier visats vara en 
riskfaktor för ett nytt missfall, men det finns också andra tänkbara förklarande 
orsaker; kromosomavvikelse hos kvinnan eller mannen, anatomiska avvikelser i 
livmodern, blodproppssjukdomar, hormonella sjukdomar (sköldkörtelsjukdom) samt 
livsstilsfaktorer (kraftig övervikt, extensiv träning). Dock, i fler än hälften av fallen 
visar utredning inte någon tänkbar eller påvisbar orsak. 
 
Försämrad blodcirkulation med ”mikroblodproppar” i moderkakan och därmed 
sämre blodtillförsel till den nyanlagda graviditeten och fostret, har framförts  
som en orsak. Men även andra orsaker har föreslagits. Utan någon säkerställd effekt 
har olika behandlingar prövats såsom blodproppsförebyggande läkemedel  
(hämning av blodets levringsförmåga), sköldkörtelhormon (tyroxin), progesteron, 
immunglobulin. 
 
Syftet med denna avhandling är att undersöka; 
 om blodproppsförebyggande behandling med acetylsalicylsyra (ASA) kan 
minska risken för nytt missfall 
 om funktionen hos blodplättar (trombocyter), små partiklar i blodet 
bidragande till blodets levringsförmåga, förändras under normal graviditet 
jämfört med kvinnors trombocytfunktion utan graviditet 
 om trombocytfunktion under normal graviditet är annorlunda jämfört med 
graviditet föregången av upprepade tidiga missfall 
 hur ASA behandling påverkar trombocyterna under graviditet 
 om avvikelser i sköldkörtelfunktionen, närvaro av tyroperoxidas (TPO)-
antikroppar eller Tyroidea Stimulerande Hormon (TSH) i övre normal-
området, kan innebära ökad risk för ett nytt missfall 
  
 
Arbete I 
 
Denna studie gjordes för att utvärdera om behandling med 75 mg ASA dagligen, 
efter påvisad graviditet, kunde minska risken för ett nytt missfall hos kvinnor med 
minst tre tidigare upprepade missfall före tretton fulla graviditetsveckor och där 
utredning inte visat något avvikande. Paren remitterades till studien från 
kvinnokliniker på sjukhus samt öppenvård, hänvisades eller tog själva kontakt för att 
få delta i studien. De flesta kom från Region Västra Götaland och Region Halland.  
Fyrahundra kvinnor, 200 kvinnor i varje grupp, lottades till ASA eller piller utan 
effekt, s.k. placebo, vid påvisad hjärtaktivitet hos fostret (graviditetsvecka 6-7) med 
ultraljud. Alla följdes med samma kontrollprogram under graviditeten. 
Trombocytfunktionen mättes hos alla kvinnorna för att mäta effekten av ASA. 
 
Resultatet visade att prognosen är mycket god för dessa kvinnor att föda barn oavsett 
ASA-behandling eller inte. Omkring 15% av kvinnorna fick ett nytt missfall inom 
varje grupp och 83% i ASA-gruppen och 85.5% i placebogruppen födde barn. 
Följsamheten till behandlingen var mycket god.  
 
Arbete II 
 
Trombocyter och dess funktion under graviditet är av stor betydelse för vissa 
graviditetskomplikationer som preeklampsi (”havandeskapsförgiftning”), dålig 
fostertillväxt, för tidig födsel och kanske även för upprepade missfall. Det är viktigt 
att studera trombocytaggregationen (blodplättarnas ”hopklumpning”) under 
graviditet för att se om behandling med läkemedel som motverkar trombocyt-
aggregationen kan minska risken för dessa graviditetskomplikationer. 
 
Sjuttionio av 104 friska gravida kvinnor utan tidigare upprepade missfall och utan 
komplikationer i aktuell graviditet, studerades avseende trombocytfunktion under 
graviditet och tre månader efter förlossning då trombocytfunktionen bedöms ha 
återgått till en normal nivå. 
 
Resultatet visade en något minskad trombocytaggregation under graviditet jämfört 
med tre månader efter förlossningen. 
 
Arbete III 
 
Arbete III gjordes för att jämföra trombocytaggregationen under graviditet hos 
kvinnor med upprepade missfall med dem som haft ett eller inget missfall, samt hur 
trombocytaggregationen påverkades av behandling med 75 mg ASA respektive med 
placebo. Trombocytaggregation studerades dessutom för att få kunskap om ASA-
  
 
effekten vid olika tidpunkter under graviditeten och jämförelse gjordes med 
trombocytaggregation före behandling. 
 
Resultaten visade att, det inte var någon skillnad i trombocytaggregation som 
aktiverats av arachidonsyra (AA) under graviditet, för kvinnor med upprepade 
missfall och de normala kontrollerna. Det finns troligen inget stöd för hypotesen  
att kvinnor med upprepade missfall skulle ha en ökad AA-aktiverad 
trombocytaggregation som förklaring till missfallen. 
 
Trombocytaggregationen hos de ASA-behandlade kvinnorna visade mer än 50% 
reduktion, vilken kvarstod för de allra flesta under hela graviditeten. Reduktionen 
minskade dock något under graviditetens senare del. Detta är inte visat tidigare och 
skulle kunna visa på ett behov att under senare del av graviditeten höja dosen av ASA 
om 75 mg per dygn används som prevention mot de tidigare nämnda graviditets-
komplikationerna.  
 
Arbete IV 
 
Underfunktion av sköldkörteln (hypotyreos) är en känd riskfaktor för missfall. Av 
den anledningen kontrolleras körtelns funktion med ett blodprov, TSH, vid 
inskrivning på mödravården i tidig graviditet, så att behandling med tyroxin kan 
sättas in vid behov. Ett annat tecken till påverkan på sköldkörteln är förekomst av 
TPO-antikroppar i blodet. Det saknas idag kunskap om TSH i sitt övre normalområde 
(2.5 <TSH ≤4.0 mU/l) med eller utan samtidig förekomst av TPO-antikroppar är 
riskfaktorer för nytt missfall hos kvinnor med tidigare upprepade missfall i första 
tredjedelen av graviditeten. 
 
I detta arbete ingick 495 av 640 kvinnor som tidigare utretts för att kunna ingå i 
studien i arbete I. Alla hade normala prover avseende TSH och fritt T4. 
Graviditetsutfall (missfall och födsel) jämfördes avseende förekomsten av TPO-
antikroppar samt nivån av TSH.  
 
Resultaten visade att TSH i sitt övre normalintervall inte var en riskfaktor för nytt 
missfall, men att förekomst av TPO-antikroppar skulle kunna vara det. 
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Introduction 
 
 
Miscarriage  
 
Miscarriage, the spontaneous loss of a pregnancy before the fetus has reached 
viability (Rai et al., 2006), is the most common complication of pregnancy. 
Miscarriage, also called spontaneous abortion, can be classified as sporadic or 
recurrent. A sporadic miscarriage occurs in 30-50% of pregnancies, but only 15% of 
cases are diagnosed (van Dijk et al., 2016; Rai et al., 2006; Kutteh et al., 2014). 
Between 12% and 24% of clinically diagnosed pregnancies end in miscarriage, 
usually in the first trimester (Lee et al., 1996), as illustrated in Figure 1 (Nybo-
Andersen, 2000). 
 
 
 
 
 
 
 
 
 
Fig. 1. Weekly risk of fetal loss. Anne-Marie Nybo Andersen. Fetal death,  
epidemiological studies. PhD thesis. University of Copenhagen. 2000.  
Published with permission from the author. 
 
Age and risk of miscarriage 
Many authors have reported an increased risk of fetal death and spontaneous abortion 
with increasing maternal age, especially over 30 years, irrespective of previous 
obstetric history (Nybo-Andersen et al., 2000; Cauchi et al., 1991; Lund et al., 2012; 
Bhattacharya et al., 2010).  
 
Reproductive behavior in our modern society has changed; many women now choose 
to delay pregnancy and childbearing. According to UK data, the number of babies 
born to women aged 35 years and up doubled between 1985 and 2001, from 8% to 
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16% of all births (Rai et al., 2006). In 1973, women in Sweden had their first child 
at a mean age of 24 years. In 2016, the corresponding age was 29.2 and in 2018 it 
was 29.4. In Danderyd, a municipality near Stockholm, the mean age at first 
childbirth was 31.8 years (highest in the country) in 2018, while it was 31.6 in 
Stockholm, 30.3 in Gothenburg (the second biggest city in Sweden) and 28.3 in 
Borås (a middle-sized city, in which the main study was conducted) (Statistics 
Sweden, 2018). In smaller cities and in rural areas, women had their first child at age 
25-26. The level of education and women wanting to establish themselves on the 
labor market before considering pregnancy and starting a family have been suggested 
as factors contributing to this variation. 
 
Nybo-Andersen conducted a prospective register study on data from the Civil 
Registration System in Denmark (Nybo-Andersen et al., 2000) between 1978 and 
1992, including 634,272 women and the outcome of 1,221,546 pregnancies. The 
overall risk of fetal loss, defined as spontaneous abortion, hydatiform mole, ectopic 
pregnancy or stillbirth, was 13.5%. More than 20% of all pregnancies in 35-year-old 
women ended in fetal loss, while this occurred in 54.5% of women aged 42 years. 
About 80% of fetal losses were spontaneous abortions. The risk of spontaneous 
abortion increased with age: 8.7% in women aged 22 years and 84.1% in women 
aged 48 and up (Fig. 2) and number of preceding spontaneous abortions (Fig. 3) 
(Nybo-Andersen et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Risk of spontaneous abortion according to maternal age at conception,  
stratified according to calendar period (Nybo-Andersen et al. Maternal age and  
fetal loss: population- based register linkage study. BMJ 2000;320:1708).  
Published with permission from BMJ/Copyright Clearance Center. 
  
 
 
19 
 
 
Fig. 3. Risk of spontaneous abortion in nulliparous women (left panel) and parous women (right panel), 
according to maternal age at conception and number of spontaneous abortions in preceding 10 years 
(Nybo-Andersen et al. Maternal age and fetal loss: population-based register linkage study BMJ 
2000;320:1708). Published with permission from BMJ/Copyright Clearance Center. 
 
 
The study demonstrated a clear independent effect of maternal age on the risk of 
spontaneous abortion, in addition to an increased risk of ectopic pregnancy and 
stillbirth with increasing maternal age (Nybo-Andersen et al., 2000).  
Recurrent pregnancy loss 
Empirically, recurrent pregnancy loss (RPL) occurs in 1-2% of fertile couples, if 
defined as at least three consecutive losses, and in 5% if the definition is two or more 
losses. According to the literature, RPL affects 0.5% to 2.3% of couples if the 
definition is at least three losses and 5% if it is defined as at least two losses (Stirrat, 
1990; Jauniaux et al., 2006; Rasmark Roepke et al., 2017). If only confirmed (by 
ultrasound and/or histology) pregnancies were included, an incidence of 0.8 to 1.4% 
has been reported. Adding loss of biochemically diagnosed pregnancies increased 
the incidence to 2-3% (Larsen et al., 2013).  
 
The definition of RPL is thus debated, ranging from two, not necessarily consecutive, 
to three consecutive miscarriages.  Unfortunately, the terminology in the literature is 
not consistent. It is difficult to compare results of different studies due to this lack of 
consensus regarding nomenclature and classification of RPL (Kolte et al., 2015). 
Most authors seem to have adopted the definitions at least three consecutive 
pregnancy losses before gestational week (gw) 13 (Clifford et al., 1997; Rai et al., 
2000; Wilson et al., 1999) or gw 20 (Jablonowska et al., 1999; Abu-Heija, 2014; 
Kaur et al., 2016). In recent years, many authors have adopted the definitions at least 
two losses before gw 13 (D´Uva et al., 2008; Bernardi et al., 2013; Pasquier et al., 
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2015) or gw 20 (Kaandorp et al., 2010; Vissenberg et al., 2015; van Dijk et al., 2016). 
Some authors apply gw 24 in their definition instead (Brigham et al., 1999; Clark et 
al., 2010). Different guidelines are presented in Table 1. 
 
Table 1. Definitions of recurrent pregnancy loss in international guidelines 
 
 
Guideline 
 
Definition 
 
American College of Obstetricians and 
Gynecologists (ACOG), 2016 
Two or more pregnancy losses before gw 24 
American Society for Reproductive Medicine 
(ASRM), RPL Guidelines 2013 
Two or more consecutive miscarriages 
European Society of Human Reproduction and 
Embryology (ESHRE), RPL Guidelines Nov. 2017; 
Hum Reprod Open 2018 
Two or more pregnancy losses before gw 24 
(RPL), or before gw 10 (REPL) 
Royal College of Obstetricians and Gynecologists 
(RCOG), Green-top Guideline No.17, 2011 
Three or more consecutive pregnancy losses 
before gw 22 
Swedish Society of Obstetrics and Gynecology 
(SFOG), Guidelines March 2017 
Three or more consecutive miscarriages before 
gw 22 
World Health Organization (WHO), 1976 Three or more consecutive miscarriages before 
gw 20 
German (DGGG), Austrian (OEGGG) and Swiss 
(SGGG) Society of Gynecology and Obstetrics; 
Geburtshilfe und Frauenheilkunde 2018;78:364-381 
Three or more consecutive miscarriages before 
gw 20 
 
RPL=recurrent pregnancy loss, REPL=recurrent early pregnancy loss, gw=gestational week 
 
RPL is classified as either primary, with no previous live births, or secondary, in 
which recurrent miscarriages are preceded by live births.  
 
About 50% of RPL are unexplained (Stirrat, 1990; Quenby et al., 1993; Clifford et 
al., 1997; Yadava et al., 2014; Homer, 2019). 
 
Based on data from the Danish National Patient Register, Knudsen et al. conducted 
a study on a large unselected Danish population consisting of 300,500 pregnancies, 
of which about 33,900 were spontaneous abortions (Knudsen et al., 1991). The 
objective was to investigate the overall risk of a new miscarriage, defined as a 
spontaneous abortion before gestational week 28, related to the number of previous 
miscarriages (Table 2). Their results are compared to results reported by other 
authors during different time periods in Table 3. 
 
To evaluate the live birth rate (LBR) within five years of the RPL investigation, 987 
women with at least three consecutive miscarriages were monitored in a prospective 
register study by Lund. The LBR was 81.3% for women aged 20-24 years, 69.9% 
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for women aged 30-34 years and 41.7% for women over age 40. Moreover, the 
number of previous miscarriages had an effect on the LBR, which was 71.9% after 
three and 50.2% after six miscarriages (Lund et al., 2012) (Fig. 4). 
 
Table 2. Risk of a new miscarriage according to age and  
number of previous miscarriages   
 
 
Number of previous 
abortions 
 
Age <35 years 
risk (%) 
 
Age ≥35 years 
risk (%) 
 
0 9.7 24.2 
1 14.9 24.0 
2 23.8 32.8 
3 43.0 54.8 
4 53.8 56.3 
 
Modified table from Knudsen et al., 1991 (Eur J Obstet Gynecol  
Reprod Biol 1991;39:31). 
 
Table 3. Risk of spontaneous abortion expressed in percentage, according to  
number of previous consecutive spontaneous abortions 
 
Author, Year 
 
Number of previous miscarriages 
 
 
1 
 
 
2 
 
3 
 
4 
Whitehouse, 1930 22 38 73 - 
Eastman, 1946   13 37 84 - 
Warburton, 1964 24 26 32 - 
Knudsen, 1991 16 25 45 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Chance of a live birth after consultation for recurrent pregnancy loss by  
number of previous miscarriages (Lund et al. Recurrent Miscarriage and  
Prognosis for Live Birth. Obstet Gynecol 2012;119:37).  
Published with permission from Lippincott Williams & Wilkins. 
 
 
22 
 
Conceivable and probable causes of recurrent pregnancy 
loss  
 
Some causes of early RPL are regarded as treatable. There are etiological factors, 
possible to identify and sometimes to treat, in up to 50% of RPL (Clifford et al., 
1997; Bricker et al., 2002; Kutteh et al., 2014). The most important of these are 
chromosomal aberration, reproductive tract malformation, luteal phase insufficiency, 
antiphospholipid syndrome, genital infection, hypercoagulable state, iatrogenic 
factors and lifestyle factors. 
 
Chromosomal aberration 
Impaired fertility and increased risk of first-trimester RPL were found when an 
aberration was carried by either the man or the woman. On investigation of RPL, a 
chromosomal aberration prevalence of 2-5% was found, mostly consisting of 
balanced translocations, compared with 0.7% in the general population (Homer 
2019; Ford et al., 2009; Rai et al., 2006). Two types of balanced translocation have 
been reported: reciprocal balanced translocation, in which there is an exchange of 
two terminal segments from different chromosomes, and Robertsonian translocation, 
i.e. centric fusion of two acrocentric chromosomes.  The most frequent versions are 
between chromosomes 13 and 14, 14 and 15 and 14 and 21, respectively. In the 
female, this can present as 45,XX,rob(14;15)(q10;q10). The carrier of a balanced 
translocation has a normal phenotype and no sign of chromosomal injury but can 
produce unbalanced gametes and an unbalanced fetus. In general, the translocation 
prevalence is higher in females than in males (Venkateshwari et al., 2010). 
 
Reproductive tract malformation  
Congenital uterine anomalies are found in 1.8% to 37.6% of women with RPL (Rai 
et al., 2006; Ford et al., 2009; Morley et al., 2013). Intrauterine septum is the most 
common congenital anomaly, and that which is most closely linked to RPL. Other 
important uterine anomalies are fibroids and polyps. Depending on the size and 
location of the anomaly, it can create poorly vascularized endometrium for 
implantation, and is thus a plausible reason for the miscarriage.  
 
Luteal phase insufficiency with progesterone deficiency 
Women with polycystic ovary syndrome (PCOS) are reported to have a RPL 
prevalence of 8-20% (Bricker et al., 2002; Kutteh et al., 2014; Rai et al., 2000). 
Insufficient progesterone exposure during early pregnancy results in impaired 
secretory endometrium, which is important for normal embryo implantation and 
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growth (Palomba et al., 2015). A positive effect of vaginal progesterone treatment 
initiated in the luteal phase was demonstrated in a randomized placebo-controlled 
trial of 700 women with unexplained RPL (Ismail et al., 2018). Highly significant 
differences in miscarriage rates (12.4% vs. 23.3%) and LBR rates (91.6% vs. 77.4%) 
were reported. However, a systematic review and meta-analysis, including the 
above-mentioned randomized controlled trial (RCT), concluded that there were too 
few studies to draw firm conclusions about the efficacy of progesterone treatment for 
women with RPL without specifically addressing luteal phase insufficiency 
(Rasmark Roepke et al., 2018). 
 
Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is an autoimmune disease that interferes with 
coagulation (Yadava et al., 2014). The prevalence of APS in women with RPL is 5-
20% (Bricker et al., 2002; Rai et al., 2006; Kutteh et al., 2014; Yadava et al., 2014; 
Homer, 2019), compared with 2-5% in unselected obstetric patients (Branch et al., 
2010). APS is the most important treatable cause of RPL. It is diagnosed by moderate 
to high blood titers of lupus anticoagulant, anti-cardiolipin antibodies and/or anti-β2-
glucoprotein-1 antibodies, at two testing occasions with an interval of at least 12 
weeks (Homer et al., 2019). It is a major risk factor underlying adverse pregnancy 
outcomes, including RPL (Kutteh et al., 2014), and the only thrombophilia with a 
proven association to RPL (McNamee et al., 2012). Women with the syndrome have 
a miscarriage rate of 90% in subsequent untreated pregnancies (Rai et al., 2006). The 
mechanisms by which APS results in RPL are insufficiently understood (Ford et al., 
2009) but thrombosis and infarction of the uteroplacental vasculature have been 
suggested as mediators (Sebire et al., 2002).  
 
Infection 
Bacterial vaginosis (BV) in the first trimester is associated with an increased risk of 
late miscarriage or preterm birth although causality has not been proven (Larsson, et 
al., 2005). The prevalence of BV in pregnant women is 15.6% to 32.5% (Svare, et 
al., 2006; Jacobsson, et al., 2002; McGregor, et al., 1995). BV was more frequent in 
women with a history of late miscarriage (21%) than in women with recurrent 
pregnancy loss (8%) (Llahi-Camp, et al., 1996), and there was no significant 
association between BV and a history of RPL (Gözde, et al., 2016). The value of 
screening and treatment in early pregnancy is under debate. 
 
  
24 
 
Inherited thrombophilia 
Prospective cohort studies have not shown any significant association between RPL 
and thrombophilia, including factor V Leiden mutation, prothrombin gene mutation, 
protein C deficiency, protein S deficiency and antithrombin deficiency.  
 
Iatrogenic and lifestyle factors 
Smoking, consumption of alcohol and caffeine intake are not associated with the risk 
of RPL (Zhang et al., 2010). Couples with RPL should, however, be informed that 
smoking and alcohol could have a negative impact on their chances of live birth, and 
cessation is thus recommended nonetheless (ESHRE Nov., 2017). Maternal obesity 
(BMI ≥30 kg/m2) significantly increased the risk of miscarriage in couples with 
unexplained RPL. There was no increased risk in non-obese women with overweight 
(Lo et al., 2012). No studies were found regarding the impact of exercise on the 
chances of live birth in women with RPL. The effect of exercise on the risk of a 
sporadic first-trimester miscarriage is unclear. In a review by Hegaard (2016) two 
studies reported that exercise was associated with a lower risk of miscarriage (Xu et 
al., 2014; Zhang et al., 2011), two others showed the same risk of miscarriage in 
exercising and non-exercising pregnant women (Maconochie et al., 2007; Clapp, 
1989) and one found an increased risk of first-trimester miscarriage in exercising 
women (Madsen et al., 2007).  High-intensity occupational activity has been 
identified as a risk factor for miscarriage (Schlussel et al., 2008). Treatment for 
cervical intraepithelial neoplasia (conization) was not associated with early 
miscarriage and RPL, although it was associated with a significantly increased risk 
of second-trimester miscarriage (Kyrgiou et al., 2014). 
 
 
Unexplained recurrent pregnancy loss 
 
As mentioned above, about 50% of RPL are unexplained.  This thesis focuses on 
investigating the respective roles of acetylsalicylic acid (ASA), platelet aggregation 
and thyroid function.  
 
 
Platelet aggregation and hemostasis  
 
Impaired platelet aggregation has been suggested to play an important role in 
placenta-mediated obstetric complications, such as RPL, preeclampsia, intrauterine 
growth retardation, impaired placental circulation and pregnancy-induced 
hypertension (Morrison et al., 1985; Dogan Gun et al., 2006; Bujold et al., 2009; 
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Flood et al., 2010; Sultana et al., 2012; Dempsey et al., 2015; Atallah et al., 2017). 
The role of platelet aggregation in unexplained recurrent miscarriage is unclear. No 
longitudinal study of platelet aggregation in women with at least three consecutive 
unexplained first-trimester RPL has been found. Furthermore, no published trial has 
demonstrated the effect of low-dose ASA on platelet aggregation during pregnancy 
in this group.  
 
Platelet aggregation  
As platelet reactivity is an important factor in placenta-mediated obstetric complica-
tions, it is of great interest to study platelet aggregation during pregnancy, since 
increased aggregation might be a factor associated with these complications. There 
are different platelet aggregation receptors on the platelet´s surface (Fig. 5).  
 
Platelet aggregation can be induced by different activators and analyzed with 
different methods, such as light transmission aggregometry, multiple electrode 
impedance aggregometry and platelet function analyzer (PFA-100) (Zimmermann et 
al., 2008; Lordkipanidzé et al., 2007). Born light transmission aggregometry is 
considered to be the gold standard (Le Quellec et al., 2016).  
 
 
 
Fig. 5. Receptors on the platelet´s surface through which different activators induce platelet 
aggregation. Published with permission from Roche Diagnostics. 
 
 
Four activators were used in these studies: 
Arachidonic acid (AA) is often used for monitoring ASA and other cyclooxygenase 
(COX) inhibitors. Platelet aggregation induced by AA is the substrate for COX. COX 
forms thromboxane A2 (TXA2) which is a potent platelet agonist and vaso- 
constrictor. 
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Collagen (COL) leads to platelet activation via the platelet COL receptor, which 
generates release of AA, which is converted to TXA2. 
Adenosine diphosphate (ADP) activates platelet aggregation through several 
receptors on the platelet surface, the most important of which is P2Y12. 
Thrombin receptor activating peptide 6 (TRAP) stimulates platelet aggregation via 
the thrombin receptor. Thrombin is a very potent platelet activator. 
 
Multiple electrode impedance aggregometry (Multiplate analyzing system) was used 
for platelet aggregation analysis in our studies. This method was chosen because of 
many advantages: the use of whole blood, no time-consuming centrifugation is 
needed, results are available within a few minutes, only a very small amount of blood 
is needed and the method is easy to handle. 
 
The analysis takes place in a single-use test cell containing a dual sensor unit and a 
Teflon-coated stirring magnet. Upon activation, the platelets adhere to and aggregate 
on metal sensor wires in the Multiplate test cell. Every Multiplate test cell contains 
two independent sensor units, each consisting of two silver-coated, highly conductive 
copper wires with a length of 3.2 mm. When platelets are activated they attach to 
vascular injuries as well as to artificial surfaces. When they adhere to the sensor wires 
the electrical resistance between the wires rises (Fig. 6). The increase in impedance 
is transformed into aggregation units (U) and plotted against time. Two curves are 
assessed using the two independent sensors in the test cell. The parameters calculated 
by the software are the mean values of the parameters determined with each curve. 
The result is shown as the area under the curve (AUC) and presented in units (U) 
(Fig. 7).  
 
 
Fig. 6. Activated platelets adhere to the metal sensor wires in the Multiplate test cell and the electrical 
resistance between the wires rises. The increase of impedance is converted into aggregation units and 
plotted against time. Published with permission from Roche Diagnostics. 
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Fig. 7. 
Area   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Area under the curve denotes platelet aggregation after activation by arachidonic acid, 
without medication (left panel) and under treatment with ASA (right panel). Red and blue denote 
parallel tests. Published with permission from Roche Diagnostics. 
U=aggregation units 
 
 
 
Multiplate multiple electrode impedance aggregometry has been used in the 
evaluation of platelet inhibitors during treatment of non-pregnant individuals 
(Jambor et al., 2009; Mueller et al., 2009; Paniccia et al., 2009; Le Quelles et al., 
2016). When it comes to pregnancy, the method has been used in a small study 
comparing platelet aggregation during normal pregnancy and preeclampsia, as well 
as in a larger study concerning non-responsiveness to ASA for prevention of 
preeclampsia (Can et al., 2010; Navaratnam et al., 2018).  
 
Normal pregnancy 
Normal pregnancy leads to changes in the coagulation and fibrinolytic systems, i.e. 
increased activity of a number of clotting factors, decrease in protein S levels, 
inhibition of fibrinolysis, and reduced activity of activated protein C, an important 
anticoagulant (Bremme, 2003). 
 
Platelet reactivity during normal pregnancy remains poorly characterized (Valera et 
al., 2010). No longitudinal study of platelet aggregation induced by different agonists 
in healthy women with uncomplicated pregnancy has been found.  
 
Conflicting results have been published regarding platelet aggregation during 
pregnancy, perhaps due to the use of different agonists and various anticoagulants 
used in blood sampling.  
 
 
 
 
200 U 
   0 U 
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Norris conducted a small study (n=20) investigating platelet aggregation in healthy 
primigravidas at gw 12, 20, 28, 32 and 36; during labor; at 1, 24 and 48 hours after 
delivery; and six weeks postpartum (Norris et al., 1993). Platelet aggregation was 
induced by AA, COL and ADP and measured by a modification of the method 
described by Fox (1982). Pregnancy had a significant effect on COL-induced platelet 
aggregation from gw 20, reaching a maximum during labor but decreasing sharply 
within 48 hours after delivery. Only a small, non-significant increase remained at six 
weeks postpartum. Platelet aggregation induced by ADP exhibited a significant 
increase at gw 36 and a slight increase at six weeks after delivery. Pregnancy had a 
significant effect on AA-induced platelet aggregation at gw 32 and 36, compared 
with gw 20, peaking during labor and gradually decreasing until 48 hours after 
delivery. In summary, the findings of this study were that platelet aggregation 
induced by AA and COL increased during normal pregnancy. Platelet aggregation 
was inhibited by ASA (Norris et al., 1993). 
 
Obstetric complications 
Platelet aggregation induced by AA and COL has been studied in pregnant women 
with gestational hypertension, essential hypertension and preeclampsia (Morrison et 
al., 1985; Norris et al., 1993). 
 
In a study by Whigham, aimed at evaluating platelet aggregation in preeclampsia, 
two control groups were included, non-pregnant women (n=11) and women with a 
normal pregnancy (n=9). No significant difference was found between the two 
control groups in platelet aggregation induced by AA, ADP and COL in a single 
sample drawn at gw 36. Platelet aggregation was measured photometrically in 0.1 ml 
of platelet-rich plasma (PRP), using the Bryston aggregometer described by Gordon 
and Drummond (1974) (Whigham et al., 1978). 
 
Recurrent pregnancy loss 
In a study by Flood, platelet aggregation in 30 women with at least three consecutive 
miscarriages before gw 20, and in 30 healthy women with normal pregnancy and no 
adverse obstetric history (one or no previous miscarriage), was investigated (Flood 
et al., 2010). Single samples were drawn in the non-pregnant state at least 12 weeks 
after the last miscarriage. There was no significant difference between the RPL and 
control groups in platelet aggregation induced by ADP, COL and TRAP. Women 
with unexplained RPL had significantly increased platelet aggregation in response to 
AA (Flood et al., 2010). 
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A study was conducted by Dempsey in order to evaluate platelet function in very 
early pregnancy in patients with at least three consecutive unexplained miscarriages. 
Patients were divided into two cohorts: women with a viable pregnancy at gw 12 and 
a subsequent live birth (n=30) and women who miscarried before gw 12 (n=9). A 
single blood test was drawn at gw 4-7. Platelet aggregation was analyzed with a 
modification of light transmission aggregometry, after induction by AA, ADP, COL 
and TRAP. In women with unexplained RPL, in whom pregnancy ended in a new 
miscarriage, there was a significant reduction in platelet aggregation in response to 
ADP and TRAP, but not to AA or COL (Dempsey et al., 2015). 
 
 
Thyroid function 
 
General aspects 
The effect of thyroid disease and autoimmunity on adverse pregnancy outcome, such 
as decreased LBR, premature delivery, miscarriage and first-trimester RPL, has been 
pointed out by many authors (van den Boogaard et al., 2011; Thangaratinam et al., 
2011; Mannisto et al., 2013; Dhanwai Kumar et al., 2016), but is also under debate. 
Hypothyroidism and subclinical hypothyroidism (SCH), defined as elevated serum 
thyroid stimulating hormone (TSH) with normal serum free thyroxine (free T4) 
levels (Vissenberg et al., 2012; van Dijk et al., 2016), are regarded as causes of 
adverse pregnancy outcome (Chan et al., 2015; Faisal et al., 2016). The effect of 
SCH in women with miscarriage is unclear. Some authors report an increased risk of 
miscarriage (van den Boogaard et al., 2011; Liu et al., 2014; Maraka et al., 2016; Ma 
et al., 2016), while some found no association at all (Bernardi et al., 2013; van Dijk 
et al., 2016; Plowden et al., 2016). Thyroid autoimmunity, detected as thyroid 
antibodies, mostly thyroglobulin antibodies and thyroid peroxidase antibodies (TPO-
ab), has been associated with increased risk of sporadic and recurrent miscarriage 
(Negro et al., 2006; Vissenberg et al., 2012; Lata et al., 2013; Meena et al., 2016; 
Wang et al., 2017). 
 
Thyroid peroxidase is an enzyme expressed in the inner membrane of the follicular 
cell within the thyroid gland (Ruf et al., 2006) and is normally undetectable by the 
immune system. The production of TPO-ab is regarded as a marker of autoimmune 
thyroid disease, as the integrity of the follicular cell is disturbed and will put the 
patient at risk of future thyroid dysfunction (Sadler et al., 2012). 
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Several pathophysiological theories have been presented to explain the proposed 
association between thyroid hormone disturbances, with or without TPO-ab, and 
subfertility and early pregnancy loss, but the exact mechanism is unknown (van den 
Boogaard et al., 2011). Some theories have focused on endometrial changes, 
involving T cells and cytotoxic natural killer (NK) cells (Nazarpour et al., 2017), 
diminished expression of trophoblast endocrine function (Maraka et al., 2017), 
down-regulation of the thyroid hormone receptors THR-A and THR-B in villous 
trophoblasts (Ziegelmüller et al., 2015) or endometrial physiology in the implantation 
process (Aghajanova et al., 2011). More general theories include autoimmunity 
against the fetal allograft (Prummel et al., 2004) and thyroid hormone deficiency 
during implantation and in the early stages of embryo development (Coliccia et al., 
2014; Vissenberg et al., 2015). 
 
Recurrent pregnancy loss 
The prevalence of TPO-ab in euthyroid women of fertile age is 8-14% (Yan et al., 
2012; Lin et al., 2014; Vissenberg et al., 2015). In euthyroid women with RPL, 
defined as at least three unexplained first-trimester miscarriages, positive TPO-ab 
were found in 10.7% and 23.5%, respectively, in two controlled studies (Ticconi et 
al., 2011; Yan et al., 2012). 
 
A two- to four-fold increased risk of both sporadic and recurrent miscarriage has 
been reported by many investigators when TPO-ab are detected in euthyroid women 
(Negro et al., 2005; Ticconi et al., 2011; Thangaratinam et al., 2011). However, other 
authors have not found any such association (Esplin et al., 1998; Lata et al., 2013; 
Plowden et al., 2016). 
 
The ultimate proof of thyroid involvement in RPL would be if thyroxine treatment 
reduced the risk of a new miscarriage. Again, some studies, both observational and 
randomized, found an effect of treatment (Negro et al., 2006; Glinoer et al., 2006; 
Lapoutre et al., 2012; Nazarpour et al., 2017), while other RCTs found no positive 
effect (Negro et al., 2016; Wang et al., 2017). The TABLET trial was published in 
2019, reporting that levothyroxine treatment before conception, in euthyroid women 
with one or more miscarriages and TPO-ab, neither decreased the miscarriage rate 
nor increased the LBR. The fact that women with as few as one miscarriage were 
included, and that no common laboratory threshold for TPO-ab levels was applied to 
all participating centers, were limitations (Dhillon-Smith et al., 2019). 
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The European Society of Human Reproduction and Embryology (ESHRE) 
concluded in their 2017 guideline that the evidence regarding treatment with 
levothyroxine in women with SCH and RPL is conflicting. Further investigation of 
this potential treatment effect is thus required. Regarding positive TPO-ab and 
levothyroxine treatment, the published studies are too small to draw any robust 
conclusion. There is insufficient evidence to support treatment with levothyroxine in 
euthyroid women with TPO-ab and RPL outside a clinical trial (ESHRE Guidelines 
Nov., 2017). 
 
One problem, when comparing studies, is the different definitions of positive TPO-
ab, which varies from 10 to 200 kU/l, according to the respective laboratory. 
Furthermore, the TSH reference values for definition of SCH vary. However, the 
lower cut-off level is 2.5 mU/l in the majority of the studies. 
 
 
Suggested treatments for unexplained recurrent 
pregnancy loss 
 
Different treatments, based on different theories regarding plausible etiologies, have 
been attempted for unexplained RPL. ASA, low-molecular-weight heparin (LMWH), 
intravenous immunoglobulin (IVIG), corticosteroids, lipid emulsion and leucocyte 
immunization have all been tried. There is no conclusive evidence that any currently 
available specific medical intervention is successful in decreasing the risk of 
miscarriage in women with unexplained RPL (Dempsey et al., 2015; Rasmark 
Roepke et al., 2018).  
 
Pharmacological treatment with ASA, LMWH, IVIG and leucocyte immunization 
have been evaluated in RCTs. For ASA and LMWH summarized in Table 4. The 
concept of “tender loving care” has also been studied, albeit only in observational 
studies.  
 
Antiplatelet and anticoagulant therapy  
The historical hypothesis behind RPL was that affected women are already in a pro-
thrombotic state before pregnancy; indeed, a positive effect of ASA in prevention of 
placental thromboses has been reported (Jahaninejad, 2014). 
 
Anti-platelet or anticoagulant drugs, or a combination, have been suggested in order 
to prevent subsequent miscarriage in women with previous early RPL. In addition to 
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preventing thrombosis, these suggestions have been grounded in different hypotheses 
concerning disturbed placental circulation, a pro-thrombotic female phenotype or 
coagulation-cascade activation of the developing trophoblasts (Geer et al., 2010). 
Pregnancy is a hypercoagulable state with increased levels of pro-coagulant factors 
(Stirling et al., 1984) and increased number of circulating endothelial microparticles 
(Carp et al., 2004).  It has thus been suggested that miscarriage is a coagulopathy 
(Rai, 2003). Significantly increased platelet aggregation induced by AA has been 
reported in women with unexplained RPL (Flood et al., 2010). Furthermore, this 
theory is supported by the fact that microthrombi and thromboses are common in 
placental vessels (Rushton, 1988; Dogan-Gun et al., 2006). 
 
Acetylsalicylic acid 
A precursor to ASA, found in willow leaves, has been used for health effects for at 
least 2,400 years. In 1853, the chemist Charles Frédéric Gerhard produced ASA for 
the first time. During the following fifty years, the chemical structure was established 
and more efficient production methods were developed. In 1899, Bayer named it 
aspirin, and its popularity spread around the world. Today, ASA is one of the most 
widely used medications globally, with about 44,000 tons, or 100 billion pills, 
consumed each year (Jones et al., 2015). It is included in the World Health 
Organization´s (WHO) List of Essential Medicines that includes the safest and most 
effective medicines needed in a health system. 
  
ASA is a non-steroid anti-inflammatory drug with anti-platelet properties that works 
primarily through inhibition of COX-1 and COX-2. COX-1 regulates the production 
of prostacyclin and TXA2. Prostacyclin is a potent vasodilator and inhibitor of 
platelet aggregation, while TXA2 is a potent vasoconstrictor and promotes platelet 
aggregation. 
 
A low dose of ASA has been used during pregnancy mostly to prevent the onset of 
preeclampsia. Other suggested indications have included prevention of RPL, preterm 
birth and fetal growth restriction. The majority of RCTs have found no increase in 
hemorrhagic complications, placental abruption, postpartum hemorrhage or mean 
blood loss associated with low-dose ASA during pregnancy (ACOG Committee 
Opinion, 2018). 
 
When it comes to the fetus, no risk of congenital anomalies has been found, although 
a possible, but very weak, association between ASA use during pregnancy and 
gastroschisis has been pointed out (Werler et al., 2002; Kozer et al., 2002). 
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Administration of ASA (60-150 mg) in the third trimester has not been associated 
with ductal closure (Sibai et al., 1989), persistent pulmonary hypertension, neonatal 
intracranial hemorrhage or other neonatal hemorrhagic complications (Duley et al., 
2007). In a study by Werler, the hypothesis that ASA taken during first-trimester 
pregnancy would increase the risk of congenital heart defects was tested. No 
increased risk, compared to that of other structural malformations, was found (Werler 
et al., 1989). The question of neonatal malformations related to ASA 50-150 mg 
daily during pregnancy was evaluated, based on Swedish Medical Birth Register 
data, by the Pharmacological Council in Region Stockholm, Sweden, in 2018. The 
studied group comprised 6,601 children whose mothers had used ASA during 
pregnancy to inhibit platelet aggregation. The total rate of malformations was 
normal, 2.3% compared with the expected 2.1%. An increased rate of cardiac 
malformations was reported in the ASA group: 63 compared with the expected 46. 
Twenty-nine had a ventricular septum defect, but 21 had an atrial septum defect, 
compared with the expected nine. The rate of hydronephrosis was also increased: 19, 
compared with the expected nine. The authors did not make any recommendation 
concerning ASA prescription during pregnancy. 
 
When it comes to the effect of anticoagulant treatment in reducing miscarriage rates 
or improving LBR, studies report diverging results. The interventions in the 
following briefly presented studies consist of ASA alone, LMWH alone, or ASA and 
LMWH in combination (Table 4). 
 
Only one RCT was found comparing low-dose ASA with placebo (Tulppala et al., 
1997). The other trials compared ASA with other drugs, alone or in combination. 
There was also a variation in study design. 
 
Based on a meta-analysis (de Jong, 2014) and the results of two subsequent large 
RCTs (Pasquier et al., 2015; Schleussner et al., 2015), there was no evidence that 
LMWH alone, ASA alone or the two in combination improved the LBR in women 
with consecutive unexplained RPL (ESHRE Guideline Nov., 2017). 
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Table 4. Interventional studies of anti-platelet and anti-coagulant treatments in women with 
unexplained recurrent pregnancy loss 
 
ASA=acetylsalicylic acid, gw=gestational week, LBR=live birth rate, RCT=randomized controlled trial; 
TLC=tender loving care 
 
 
  
Author, 
year 
Study design, 
participants, n 
Previous 
miscarriages 
Treatment,  
participants, n 
Outcome Comments 
Pasquier 
2015 
Multicenter RCT 
n=256 
≥2 consecutive 
before gw 15 
Enoxaparin 40 mg 
(n=138) / placebo 
(n=118) 
Live birth 
66.6% vs. 72.9% 
Stratified for no. 
of previous 
miscarriages and 
age  
Schleussner 
2015 
Multicenter RCT 
n=434 
≥2 consecutive 
before gw 13 
Dalteparin 5000 
IU (n=220)/ 
multivitamin pills 
(n=214) 
Ongoing 
pregnancy at  
gw 24  
86.8% vs. 87.9% 
Live birth  
86.0% vs. 86.7% 
 
Clark 
2010 
Multicenter 
RCT (SPIN) 
n=294 
≥2 consecutive 
before gw 24 
Enoxaparin 40 mg 
and ASA 75 mg 
and TLC (n=147)/ 
TLC alone 
(n=147) 
Miscarriage  
22% vs. 20% 
 
Kaandorp 
2010 
Multicenter 
RCT (ALIFE) 
n=364 (enrolled), 
n=310 (pregnant) 
≥2 before gw 20 ASA 80 mg and 
fraxiparine 2850 
IU (n=103)/ASA 
80 mg alone 
(n=104)/placebo 
(n=103) 
Live birth  
54.5%, 50.8% and 
57.0% 
400 µg folic acid 
to all participants 
during pregnancy 
Badawy 
2008 
Single-center  
RCT 
n=340 
≥3 first-trimester  Enoxaparin 20 mg 
(n=170)/no 
treatment (n=170) 
Miscarriage  
4.1% vs. 8.8% 
(early) 1.1% vs. 
2.3% (late) 
500 µg folic acid 
until  gw 13 to all 
participants 
Dolitzky 
2006 
 
Multicenter RCT,  
single-blind 
n=107 
≥3 consecutive 
first-trimester or 
≥2 second- 
trimester  
Enoxaparin 40 mg 
(n=54)/ASA 100 
mg (n=50) 
Lost to follow-up 
(n=3) 
Live birth  
81.5% vs. 84.0% 
No placebo group 
 
Tulppala 
1997 
Single-center 
RCT 
n=54 
 ASA 50 mg 
(n=27)/placebo 
(n=27) 
Live birth  
81.5% vs. 81.5% 
 
Elmahashi 
2014 
Single-center 
RCT, open  
n=150 
≥3 consecutive Enoxaparin 40 mg 
and ASA 75 mg 
(n=75)/ASA 75 
mg (n=75) 
Miscarriage  
29% vs. 47% 
Live birth  
71% vs. 42% 
High miscarriage 
rate, low LBR and 
preterm delivery 
rate about 23% 
Rai 
2000 
Single-center 
observational 
study 
n=805 
≥3 consecutive 
before gw 13 
ASA 75 mg 
(n=367)/no 
treatment (n=438) 
Live birth  
68.4% vs. 63.5% 
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Immunoglobulin 
Jablonowska conducted a double-blind RCT (n=41) to evaluate the effect of 
treatment with IVIG (20g/400ml Gammonativ, n=22), compared with placebo 
(400ml saline, n=19), in order to prevent new miscarriages in a group of women with 
three or more consecutive unexplained miscarriages before gw 20. All previous 
pregnancies were documented by ultrasound or histology. The LBR was 77% for 
IVIG and 79% for placebo (Jablonowska et al., 1999). Another five RCTs were 
evaluated by Rasmark Roepke in a systematic review. IVIG was compared with 
placebo in four studies, but the placebo drugs were different (three albumin and one 
saline). IVIG was compared with ASA+LMWH in the fifth study. No significant 
effect on LBR was shown (Rasmark Roepke et al., 2018). 
 
Leucocyte immunization 
Gatenby published a double-blind RCT comparing immunization with 400 million 
paternal lymphocytes and immunization with 400 million autologous lymphocytes, 
in women with at least three consecutive confirmed miscarriages before gw 20. 
Treatment started before pregnancy and was repeated every 12 weeks until positive 
pregnancy test. LBRs were 68% and 47% for paternal and autologous lymphocyte 
immunization, respectively (p=0.1) (Gatenby et al., 1993). In the systematic review 
by Rasmark Roepke, another four RCTs were evaluated. There were design 
differences between all trials in terms of start and of testing time-points. The trials 
were old (published between 1985 and 1994) the results were not trustworthy due to 
very low certainty of evidence based on a high risk of bias and severe imprecision 
(Rasmark Roepke et al., 2018). 
 
Psychological support/tender loving care  
As early as in in 1954, Javert wrote about the need for psychotherapy for patients 
with RPL. A therapeutic regimen, including a pre-conceptional consultation for the 
patient and her partner, and examination for detection of specific medical, 
gynecological and psychological factors, was offered. Frequent prenatal visits and 
unlimited phone calls in order to relieve anxiety were also included. “It has been our 
practice since 1940 to establish a pre-conceptional interview with the patient. The 
patient was allowed to verbalize her past experiences with the miscarriages, doctors, 
hospitals and her attitude toward another pregnancy. Then she was referred, with her 
partner, to the psychosomatic consultant for more detailed review” (Javert, 1954). 
When these patients had had a successful pregnancy, their subsequent pregnancies 
were uncomplicated. According to this author, repeat miscarriage is in itself a stress 
mechanism which may lead to rejection of the next pregnancy (Javert, 1954). 
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Musters did something very similar: a questionnaire study of 174 women with at 
least two previous miscarriages. The women preferred a plan for the first trimester 
in a subsequent pregnancy that involved one single doctor and repeated ultrasounds, 
as well being shown understanding and being listened to. Furthermore, they wanted 
healthcare staff to be aware of their obstetric history and show respect for them and 
their miscarriages (Musters et al., 2013).  
 
Couples with recurrent miscarriage have higher levels of depression, anxiety and 
feelings of guilt, compared with the general population. Therefore, patients may 
benefit from regular contact with a dedicated miscarriage clinic (Morley et al., 2013; 
Fertl et al., 2009; Homer, 2019; Rai et al., 2006). When a follow-up clinic was 
established, 79% of women with previous recurrent miscarriage attended, and they 
all found the contact helpful (Lee et al., 1996).  
 
A third of the women seeing psychiatric specialists due to RPL are clinically 
depressed, and about 20% have anxiety symptoms similar to those in general 
psychiatric outpatient populations. It is evident that anxiety symptoms may occur in 
response to miscarriage (Lee et al., 1996).  
 
In 1962, Tupper and Weil suggested that psychotherapy should be included as part 
of the treatment of RPL. A group of women with three previous consecutive 
miscarriages, given psychotherapy in the subsequent pregnancy, had a LBR of 84%, 
compared to 26% in the control group (Tupper et al., 1962). James also concluded 
that psychotherapy had a positive effect in reducing RPL, as the LBR was 80% in 
the therapy group, compared with 42% in the group not given therapy (James et al., 
1963). However, the small study populations and a major risk of selection bias, 
constitute limitations in these three old observational studies. The results are thus not 
applicable.  
 
Supportive care as the sole treatment has been described in several case series, 
reporting 70-86% LBR in subsequent pregnancies in women with unexplained RPL 
(Badawy et al., 2008; Fawzy et al., 2008; Brigham et al., 1999; Bricker et al., 2002). 
 
In a study by Stray-Pedersen of couples with three or more unexplained consecutive 
miscarriages, the LBR was 86% after special psychological support, compared with 
33% after routine prenatal care (Stray-Pedersen et al., 1984). The same levels, 86% 
and 33%, respectively, were found by Liddell, although the fact that the control group 
included only nine women was a limitation (Liddell et al., 1991). These authors 
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concluded that psychological support alone may lead to a significant improvement 
in the outcome of pregnancy. 
 
In summary, the studies on supportive care alone are all observational and suffer 
from major methodological drawbacks. Rai suggests that patients with RPL should 
be referred to placebo-controlled trials, in order to elucidate the value, shown in 
previous studies, of psychological support in improving pregnancy outcome (Rai et 
al., 2006). This suggestion is wise, since all individuals participating in prospective 
trials will be thoroughly monitored and taken care of, which will likely be beneficial 
for women with RPL.  
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Aims 
 
 
Aims of the thesis; 
 
 to investigate whether a low dose of ASA, 75 mg daily, during pregnancy can 
prevent a new miscarriage in women with at least three consecutive 
unexplained first-trimester miscarriages in the current relationship (Paper I) 
 
 to study platelet aggregation in healthy women during normal pregnancy 
longitudinally by multiple electrode impedance aggregometry and compare it 
with platelet aggregation in the non-pregnant state (Paper II) 
 
 to compare platelet aggregation during pregnancy in women with and without 
RPL for unknown reasons (Paper III)  
 
 to study the effect of ASA on platelet aggregation in women with RPL during 
pregnancy longitudinally and in comparison with healthy pregnant women 
(Paper III) 
  
 to investigate the effect of TPO-ab and of TSH levels in the upper normal 
reference range on the risk of first-trimester miscarriage in women with a 
history of early RPL (Paper IV) 
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Methods 
 
 
Study populations 
 
The main study population consisted of women with RPL. One RCT (Paper I) and 
two post hoc studies (Papers III and IV) were derived from this screened population. 
A population of healthy women with normal pregnancy constituted the study 
population in Paper II and contributed a comparison group in Paper III. The 
formation of the final study populations in the four papers is presented in two flow 
charts (Figures 8 and 9). The specific methodology related to each paper is presented 
below. 
 
 
 
 
 
Fig. 8. Flow chart of the study populations of women with recurrent early pregnancy loss. 
Abbreviation: ASA-RCT=randomized controlled trial on preventive effect of acetylsalicylic acid for 
recurrent miscarriage; TPO-ab=thyroid peroxidase antibodies 
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Fig. 9. Flow chart of the study populations of healthy women with normal pregnancy. 
Abbreviation: AA=arachidonic acid 
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Study populations of women with recurrent pregnancy loss 
 
Randomized pregnant women with unexplained first-trimester recurrent 
pregnancy loss 
 
Paper I: Acetylsalicylic acid does not prevent first-trimester unexplained recurrent 
pregnancy loss: a randomized controlled trial 
 
After promising results in a pilot case series, the planning of an RCT, hereafter 
referred to as the ASA-RCT, to test the hypothesis that low-dose ASA would prevent 
miscarriage, started in the spring of 2007. Later the same year, the principal 
investigator (PI) visited gynecology departments and clinics in order to inform 
gynecologists and general practitioners about the trial. Figure 10 describes how 
women came to screening for the ASA-RCT.  
 
The primary geographical inclusion area was chosen in response to the question 
“How long would a couple accept to travel for examination, monitoring and taking 
part in a study of recurrent miscarriage?” Information about the RCT was also spread 
by newspapers and radio. Many couples, even some living very far away, were 
referred by their local doctors or contacted the PI themselves, wanting to participate 
in the study. Most couples came from Region Västra Götaland and Region Halland 
(n=534) in western Sweden, while some came from other parts of Sweden (n=85). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. Distribution of the 619 screened women in the ASA-RCT, according to  
type of referral unit. ASA-RCT=randomized controlled trial on preventive effect  
of acetylsalicylic acid for recurrent miscarriage 
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Screening phase 
All women had a primary interview by phone with the PI. Medical and obstetrical 
history and heredity were discussed, and inclusion/exclusion criteria were checked. 
If nothing abnormal emerged during the interview, the couple was booked for an 
appointment with the PI for examination and further information about the study.  
 
The workup included general and gynecological examination, transvaginal 
ultrasound, hydrosonography of the uterine cavity and blood pressure measurement. 
Laboratory blood tests included hemoglobin (Hb); leucocyte count (LC); platelet 
count (PC); activated partial thromboplastin time (APTT); prothrombin complex 
(INR) (PC(INR)); liver enzymes; kidney function; plasma glucose; thyroid function; 
chromosome analysis; and coagulation tests, including analysis for thrombophilia, 
antiphospholipid syndrome and lupus anticoagulant.  
 
The workup for the male partner included lifestyle, heredity and chromosome 
analysis.  
 
Eligiblity 
Inclusion criteria were a history of at least three consecutive first-trimester 
(maximum gestational length 12 weeks and 6 days) miscarriages in the current 
relationship, no abnormalities in the workup, body mass index (BMI) <35 kg/m², age 
<40 years at the start of the investigation and no allergy to ASA. Women with 
ongoing conflicting medical treatment, conception by in vitro fertilization (IVF) on 
RPL indication or previous participation in the study were excluded. All clinical data 
were collected at the Department of Obstetrics and Gynecology at Södra Älvsborg 
Hospital, Borås, Sweden.  
 
Written consent was provided by both partners. All screened couples were seen by 
the PI, who was responsible for assessing eligibility. The eligible women were 
provided with the number of the “study cellphone”. After the woman had conceived, 
she reported the positive pregnancy test (human chorionic gonadotropin (hCG) in 
urine) to the PI. A total of 498 women were eligible in the ASA-RCT (Fig. 8).  
 
Randomization 
When a woman reported a positive pregnancy test to the PI, she was booked for a 
visit to confirm a viable pregnancy. If a fetal heartbeat was detected, a form was 
filled in and faxed to the pharmacy at Södra Älvsborg Hospital, Borås, where it was 
completed with a code number in consecutive order.  
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The randomization was stratified for age (<33/≥33 years), in blocks of 20 and with a 
1:1 ratio, for ASA and placebo, in order to ensure similar age-related fertility in both 
groups. The cut-off age 33 was based on the median in the pilot case series of women 
with RPL. Both the randomization list and the key code were computer-generated by 
Apoteket Produktion & Laboratorier (APL), Stockholm, Sweden. The study parcels 
were produced, labeled and numbered by APL and sent to the pharmacy at Södra 
Älvsborg Hospital. The parcel was collected by the patient, either at that pharmacy 
or at another hospital pharmacy. If ordered before 4 AM, the parcel reached the other 
hospital the next day. 
 
The study drug  
In November 2007, APL started production of treatment capsules. The substrate 
ASA was supplied by Pfizer AB (Sollentuna, Sweden).  
  
The ASA capsules consisted of 75 mg ASA, cellulosum microcristallinum PH 102, 
Ph Eur 260 mg and capsulae gelatinosae size 0, caramel opaque. The product weight 
was checked in 5/150 produced capsules, with an accepted difference of ±5%. The 
capsules were also checked for identity according to the ITAKA-system (Identity of 
TAblets and KApslar (capsules) and tested positive for ASA, quantitative titration of 
ASA, decomposition (≤30 minutes according to Ph Eur) and microbiology 
(according to Ph Eur Category 3). Appearance, quantitative titration of ASA and 
decomposition were re-checked after 18 and 36 months.  
 
The placebo capsules consisted of cellulosum microcristallinum PH 102, Ph Eur 300 
mg and capsulae gelatinosae size 0, caramel opaque. The production process was 
checked for 10 capsules at every 15 minutes. The accepted difference in capsule 
weight was ±5%. The placebo capsules were also checked for appearance and 
identity according to ITAKA and tested for absence of ASA, decomposition and 
microbiology. Appearance and decomposition were re-checked after 18 and 36 
months. 
 
Every study parcel contained three jars, each containing 70 ASA or placebo capsules. 
The parcels and capsules were identical in appearance. They were produced in two 
series to ensure drug efficacy over time. 
 
Follow-up during and after pregnancy 
Patients were checked at clinical visits at gw 9, 13, 30 and 36 and by telephone call 
at gw 20. The visits included ordinary prenatal monitoring, assessment of fetal 
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growth, registration of adverse events including vaginal bleeding and inquiring about 
side effects of treatment. The study drug was discontinued at gw 36. The PI made a 
final summary, focusing on the final weeks of pregnancy, delivery and early 
postpartum period, by phone three weeks after delivery.  
 
 
Randomized pregnant women with unexplained recurrent early pregnancy 
loss and normal platelet aggregation before pregnancy 
 
Paper III: Platelet aggregation during pregnancy in women with previous recurrent 
first trimester fetal loss, with and without acetylsalicylic acid treatment 
 
A post hoc study was performed on a population of women with normal platelet 
aggregation, induced by AA and analyzed with multiple electrode impedance 
aggregometry, the ASPI test, in the non-pregnant state. Two groups were derived 
from the study population of women with RPL. Inclusion criteria were randomization 
in the ASA-RCT and normal AA-induced platelet aggregation before pregnancy. 
Among ASA-treated women, 176 had an ASPI test before pregnancy, of which 160 
yielded results within reference limits. The corresponding numbers for women 
treated with placebo were 177 and 163. Table 5 presents the time-points for blood 
sampling and laboratory analyses. 
 
 
Table 5. Blood sampling occasions for the laboratory analyses during pregnancy and in the 
non-pregnant state, Papers I, II and III 
Laboratory  
methods  
Non-
pregnant* 
Gestational week 
13 8-15 20 20-22 30 30-33 36 37-40 
MP AA I/ II/III I/III II/III  II/III I/III II/III I/III II/III 
MP ADP II/III  II/III  II/III  II/III  II/III 
MP collagen II/III  II/III  II/III  II/III  II/III 
MP TRAP II/III  II/III  II/III  II/III  II/III 
Platelet count I/II/III  II/III I/III II/III  II/III  II/III 
Hemoglobin I/III   I/III      
PC(INR) I/III   I/III      
APTT I/III   I/III      
 
Roman numbers refer to the respective papers. AA=arachidonic acid, ADP=adenosine diphosphate, 
MP=Multiplate, TRAP=thrombin receptor-activating peptide Trap-6, PC(INR)=prothrombin complex 
(international normalized ratio), APTT (activated partial thromboplastin time) 
*Blood samples for Paper II and for controls in Paper III in the non-pregnant state were collected 
three months post-partum. 
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A third group was derived from the study population of healthy women with normal 
pregnancy and is presented below under that heading.  
 
 
Pregnant women (including biochemical pregnancies) with unexplained 
recurrent early pregnancy loss, normal TSH and analyzed TPO antibodies 
 
Paper IV: Pre-conceptional thyroid peroxidase antibody positivity in women with 
recurrent pregnancy losses may be a risk factor for another miscarriage 
 
A cohort was retrieved from the study population of pregnant women with RPL. This 
cohort included women that were either screened in the ASA-RCT, or outside the 
trial using the same eligibility criteria (Fig. 8). Conception (at least a positive 
pregnancy test) and blood sampling for thyroid hormone analyses were additional 
inclusion criteria. A very early loss of a pregnancy confirmed only with a pregnancy 
test was defined as a biochemical pregnancy. As part of the screening phase before 
pregnancy, blood samples were taken for analysis of TSH, free thyroxine (T4) and 
TPO-ab.  
 
Missing thyroid tests, TSH >4 mU/l and non-retrievable pregnancy outcome were 
exclusion criteria.  In total 495 women were included (Fig 8).  
 
 
Study populations of healthy women with normal pregnancy 
 
Healthy women with normal pregnancy 
 
Paper II: Platelet aggregation in healthy women during normal pregnancy - a 
longitudinal study 
 
Women in early pregnancy were invited to take part in a study of platelet aggregation 
with multiple electrode impedance aggregometry using the Multiplate analyzing 
system. During the period October 2011 to December 2012, women at gw 6-10 were 
registered at their first visit to the primary care Prenatal Clinic in Borås, Sweden. 
They received oral and written information during their first visit to the midwife. If 
the woman was interested in participation, she was contacted by phone and 
interviewed by the PI about her medical and obstetric history as well as the inclusion 
and exclusion criteria. If nothing abnormal emerged, written consent was provided 
and the woman was included.  
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The inclusion criteria were: healthy woman, age <40 years, none or one previous 
miscarriage, willing to come in four times during pregnancy and once three months 
postpartum for blood sampling. 
 
Exclusion criteria were: previous pregnancy complicated by preeclampsia/ 
eclampsia, hypertension, thyroid disease, diabetes mellitus or other chronic illness, 
BMI <35 kg/m², current smoking, family history of thromboembolic or bleeding 
disease and current medical treatment affecting hemostasis, including platelet 
function. 
 
Since no blood sampling was possible before pregnancy in this group, the post-
partum state was used to assess platelet aggregation in the non-pregnant state.  
 
A total of 114 women accepted participation, of whom 104 were eligible and 79 were 
finally included in the study (Fig. 9). Blood samples for analysis of PC, and platelet 
aggregation by the four activators AA, COL, ADP and TRAP were collected at gw 
8-15, 20-22, 30-33 and 37-40 and three months postpartum (Table 5). 
 
 
Healthy women with normal pregnancy and normal platelet aggregation in the 
non-pregnant state  
 
Paper III: Platelet aggregation during pregnancy in women with previous recurrent 
first trimester fetal loss, with and without acetylsalicylic acid treatment 
 
This study population derived from Study II served as a control group in Study III, 
in order to compare platelet aggregation during pregnancy in women with RPL with 
that in a control group of healthy women with normal pregnancy.  Inclusion criteria 
were AA-induced platelet aggregation within reference limits in the non-pregnant 
state. This control group comprised 59 women.  
 
 
Laboratory methods 
 
All participants  
Blood sampling from the brachial vein was performed between 7 AM and 3 PM at 
the Department of Clinical Chemistry, Södra Älvsborg Hospital, Borås. Most blood 
samples were centrifuged at 20°C for 10 minutes at 2,000 g within two hours and 
stored at -20°C if not analyzed the same day. Platelet aggregation analyses were 
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performed on fresh whole blood. All laboratory analyses were analyzed at the same 
department, except coagulation and immunological samples, which were sent to the 
Departments of Coagulation and Immunology at Sahlgrenska University Hospital, 
Gothenburg, Sweden, for analysis. Most biochemical data were collected and stored 
at the Department of Clinical Chemistry, Södra Älvsborg Hospital, Borås. Results of 
blood tests analyzed at Sahlgrenska University Hospital were stored with the medical 
records at the Department of Obstetrics and Gynecology, Södra Älvsborg Hospital, 
Borås. 
 
Laboratory analyses during the screening phase of the ASA-RCT 
The routine tests Hb, LC, PC, liver enzymes, kidney function, thyroid function and 
glucose were analyzed according to ordinary routine methods. 
 
Coagulation tests, including screening for thrombophilia, antiphospholipid-
antibodies, and chromosome analyses were performed with ordinary routine 
methods. 
 
Platelet aggregation was determined with the Multiplate analyzer method (Roche 
Diagnostics International Ltd, Rotkreutz, Switzerland). The blood samples were 
collected in two 3-ml tubes containing hirudin 25 µg/ml and were handled within 
30–180 minutes, according to the manufacturer’s instructions.  The results were not 
reported by the laboratory until after the study closed. Multiple electrode impedance 
aggregometry (Multiplate analyzer), using the ASPI test with AA as the initiator, was 
used as indicator of ASA effect.  
 
An ASPI value <30 aggregation units (U) during ASA treatment was used as the cut-
off for normal ASA response, in line with the manufacturer’s instructions (Calatzis 
et al., 2004; Lenk et al., 2013; Toth et al., 2006). Non-responders to ASA were 
defined as women with ASPI ≥30 U at every test occasion during ASA treatment. 
Changes in AA-induced aggregation corresponding to a 30%, 40% and 50% 
reduction from the non-pregnant state were also determined. 
 
Due to a technical delay, the Multiplate analyzing system was not available when the 
first study patients in the ASA-RCT had their initial visit with the PI. Therefore, 47 
women did not have an ASPI test before pregnancy.                                              
 
TSH, free T4 and TPO-ab were all determined by routine methods. The samples were 
collected in BD Vacutainer Lithium Heparin PST II, 3 ml. In this study, the upper 
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normal range for TSH was defined as 2.5 <TSH ≤4.0 mU/l. Positive TPO-ab was 
defined as ≥10 kU/l, corresponding to the laboratory’s cut-off value. 
 
Blood sampling periods and laboratory analyses in the studies  
Platelet aggregation with AA as activator, PC, Hb, activated partial thromboplastin 
time (APTT) and prothrombin complex (international normalized ratio) (PC(INR)) 
were determined during pregnancy and post-partum. Time-points for blood sampling 
are shown in Table 5. 
 
In addition, ADP, COL and TRAP were used as activators of platelet aggregation 
during pregnancy and postpartum in Paper II (see Table 5). 
 
 
Statistical analyses 
 
Sample size calculations 
 
Paper I 
To detect a 15% difference in LBR, given a reference level of 50%, α=0.05, β=0.20 
and a two-sided Fisher´s exact test, 170 patients were required in each group. A total 
of 400 patients was the final target for recruitment, allowing for a 10% loss to follow-
up.  
 
Paper II 
The number of included women was based on an estimation of how many could be 
included within a reasonable time period. There were no previously published data 
on Multiplate analysis in a pregnant population on which to base a formal power 
calculation. 
 
Paper III 
The sample sizes in the different groups were determined by availability of ASPI test 
results in the non-pregnant state among the eligible subjects in the two original 
studies (Blomqvist et al., 2018; Blomqvist et al., 2019).  
 
Paper IV 
The sample size was determined by the availability of complete thyroid laboratory 
analysis results and pregnancy outcomes in the study population of pregnant women 
with RPL.  
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Statistical methods 
 
A summary of the applied analyses in the four papers is presented in Table 6.  
 
Table 6. Statistical methods applied in the papers 
Statistical methods Paper I Paper II Paper III Paper IV 
Descriptive analyses. Mean, SD, median, 
minimum; maximum or Q1; Q2 for 
continuous variables. 
Numbers and % for categorical variables 
X X X X 
For comparisons between two groups: 
Fisher´s exact test for dichotomous variables X X  X 
Mann-Whitney U test for continuous 
variables that are not normally distributed 
X X X X 
Two-sample t-test for normally distributed 
continuous variables  
 X   
Mantel-Haenszel Chi-square test for 
ordered categorical variables 
   X 
For other analyses: 
Wilcoxon signed rank test for analysis of  
change within groups 
X X X  
Linear regression, followed by Wilcoxon 
Signed Rank Test to analyze whether beta 
coefficients (slopes) differ from zero over 
subjects 
 X   
Spearman´s correlation coefficient for 
cross-sectional correlation analysis 
 X  X 
Generalized linear model with binomial 
distribution for the dependent variable, and 
log-link function to estimate adjusted risk 
ratio with 95% confidence interval 
   X 
Stepwise logistic regression for selection of 
risk factors 
   X 
 
 
Descriptive statistics 
Categorical variables are presented with number and percentages. Continuous 
variables are presented with mean, standard deviation (SD), median, minimum/ 
maximum or quartiles (Q1, Q3).  
 
Comparisons between groups 
The Fisher´s exact test was used for dichotomous variables, the Mantel-Haenszel 
Chi-square test for ordered categorical variables, the Mann-Whitney U test was used 
for non-normally distributed continuous variables and the two-sample t-test for 
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normally distributed variables. Risk differences and risk ratios with 95% confidence 
intervals (CI) were calculated. Mean differences with 95% CI for continuous 
variables were bootstrapped with 10,000 re-samplings. 
 
Comparisons within groups 
The Wilcoxon signed rank test was used for analysis of changes over time for 
continuous variables within-groups.  
 
Correlation and regression analyses 
Spearman´s correlation coefficient was used for all cross-sectional correlation 
analyses. Linear regression analysis was used for calculation of individual beta 
coefficients (slopes) for trend over time. These slopes was analyzed with the 
Wilcoxon signed rank test, to assess whether these slopes differed from zero over 
subjects.  
 
Generalized linear models with binomial distribution for the dependent variable, and 
log-link function were used to estimate unadjusted and adjusted risk ratio (RR) with 
95% confidence interval (CI). RR with exact 95% CI for the estimated proportions 
were calculated. Stepwise logistic regression was applied to found important risk 
factors presented with odds ratio (OR) and 95% CI. 
 
All significance tests were two-sided and conducted at the 5% significance level.   
All analyses were performed using the SAS System version 9 (SAS Institute, Cary, 
NC, USA). 
 
 
Regulatory approvals 
 
Permission for drug testing with ASA 75 mg was given by the Swedish Medical 
Products Agency on Oct. 2, 2007 (Eudra Clinical Trial Application number (Eu-nr) 
2007-003839-24, number 151:2007/48666). 
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Ethical considerations 
 
Ethical considerations must always be evaluated when planning a trial: 
 
• Will randomization, intervention, control treatment and/or follow-up intervene 
with the patient’s integrity or autonomy? 
• Will the trial cause displacement effects?  
• Is the trial very costly and will any potential benefit be cost-effective?  
 
During the planning of the ASA-RCT, we found that women with RPL had been 
treated with low-dose ASA despite unproven benefit, which we considered to be 
unethical and a reason to conduct the trial. No safety issues with low-dose ASA were 
evident from the literature. After the launch of the trial, patients actively sought 
participation and they did not consider their integrity or autonomy to be threatened 
by the study protocol. No displacement effects were anticipated by antenatal clinic 
staff and the RPL population could be referred to the PI and the department of 
gynecology where the study was conducted. 
 
Since ASA is very cheap, any treatment regimen would be cost-effective if it were 
proven to be effective. Now, after the trial has been conducted and ASA proven 
ineffective when initiated after verification of a viable fetus at gestational week 6-7, 
it would instead raise ethical concerns to administer ASA treatment under these 
conditions.  
 
In the other study population, participants were healthy women with normal 
pregnancies who chose to participate and contribute their free time.  
 
All studies were conducted in accordance with the Declaration of Helsinki. The 
Regional Ethical Review Board at the University of Gothenburg approved the ASA-
RCT (Papers I, III, IV) on July 18, 2007 (number 234-07) and the study of platelet 
aggregation in healthy pregnant women (Paper II) on July 21, 2010 (number 366-
10). 
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Results 
 
 
Of the 619 screened women, 51 were excluded after the telephone interview but 
before the medical investigation, due to age ≥40 years (n=34) or incorrect 
miscarriage history (n=17). The reasons for exclusion after medical investigation 
were chromosomal aberration (n=15), thyroid disease (n=11), abnormal laboratory 
test results (n=8), uterine anomaly (n=2), BMI >35 kg/m2 (n=3) and dropped out 
before inclusion (n=31). A total of 121 women were excluded. If the results of the 
investigation were normal, the woman was included in the study after providing 
written consent. Randomization occurred after a positive pregnancy test and 
detection of fetal heartbeat by vaginal ultrasound. 
 
Of the 498 included women, 98 were not randomized due to failure to become 
pregnant after investigation (n=34), no longer planning pregnancy (n=8), miscarriage 
before randomization (n=7), adoption (n=8), divorce (n=7), dropped out for personal 
reasons or other reason (n=34). Four hundred women were finally randomized to 
treatment with ASA or placebo (Fig. 8). 
 
 
Paper I 
 
The mean age in the study group was 32.3 (SD 4.3) years and the mean BMI was 
23.9 (SD 3.8) kg/m2.  The women had had three to seven consecutive miscarriages. 
Fifty-two percent of the couples had primary RPL, i. e. no children born before the 
miscarriages. The obstetric and medical history and demographic variables were 
evenly distributed between the randomization groups except smoking, which was 
less prevalent in the placebo group. Ninety-eight percent were singleton pregnancies, 
and the remaining 2% were twin pregnancies, four in each randomization group. 
 
The randomization rate was fairly constant after the first year (Fig. 11). The first 
woman was randomized at the very beginning of March 2008 and the last at the end 
of October 2015.  
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Fig. 11. Number of randomized women per year in the ASA-RCT. 
 
 
Approximately 90% of the visits at randomization and during follow-up, and all 
visits at Södra Älvsborg Hospital, were with the PI. The remaining visits were carried 
out at other hospitals’ or gynecologic outpatient clinics, mostly due to long distances 
from the study site.  Not all pregnant women were physically examined toward the 
end of pregnancy, due to difficulties related to long journeys, especially if they had 
symptoms that made it difficult to travel. Single physical visits that did not occur for 
these reasons were replaced with a subsequent check-up by phone. All delivery 
records were submitted to the PI, followed by a phone call with the woman. All 
participants reported absolute adherence to treatment. 
 
LBR, the primary outcome of the study, did not differ in the ASA and placebo groups 
(83.0% vs. 85.5%) in the intention-to-treat analysis. The difference was -2.5% (95% 
CI -10.1% to 5.1%).  
 
There were similar rates of pregnancy loss in the two treatment groups. In the ASA 
group, four of five women with late miscarriages (gw 17-21) had a verified uterine 
infection. The reason for a second-trimester termination of pregnancy was 
hydrocephalus, detected at routine ultrasound at gw 19+2 days. In the placebo group, 
one intrauterine fetal death occurred at gw 42. There were few obstetric 
complications, such as placenta previa, preeclampsia and pregnancy-induced 
hypertension, and rates were similar in the two study groups. Five (2.5%) and 13 
(6.5%) women had a preterm delivery in the ASA and placebo group, respectively. 
Six (3.6%) and four (2.3%) babies in the ASA and placebo group, respectively, were 
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small for gestational age. Miscarriage, either early or late, occurred in 33 (16.5%) 
and 28 (14.0%) in the ASA and placebo group, respectively (RR 1.18 (95%CI 0.74 
to 1.87, p=0.58). Pregnancy outcomes for all women in the ASA-RCT are shown in 
Fig. 12. 
 
Platelet aggregation was analyzed as a test of compliance and showed a marked 
decrease in ASA-treated women, as shown in Figure 2 in Paper I. 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Pregnancy outcome among 400 randomized women in the ASA-RCT. 
PL=pregnancy loss 
 
 
Paper II 
 
A total of 114 pregnant women accepted participation. Ten women were excluded 
before start due to chronic illness, BMI ≥35 kg/m2 or current smoking. Another 25 
women were excluded after delivery due to complicated pregnancies. The remaining 
79 women had uncomplicated pregnancies and gave birth at term to healthy babies. 
The mean age was 29.1 (SD 4.8) years and the mean BMI was 23.0 kg/m2 (SD 3.1).  
Postpartum (8-12 weeks after delivery) samples from 19 participants were missing.  
 
Lower platelet aggregation at gw 8-15 and 37-40, compared with postpartum, was 
found after activation with AA, ADP and TRAP. Platelet aggregation after induction 
with COL was unaltered. A minor increase in ADP-induced aggregation was found 
as pregnancy proceeded (Table 3 in Paper II). AA-, COL- and TRAP-induced 
aggregation exhibited no change over time during pregnancy. 
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PC from all sampling occasions were not available for all participants. Platelet 
aggregation was therefore compared between women with known and unknown PC. 
There were no statistically significant differences in platelet aggregation with any 
activator between women with and without PC determined at the different analysis 
points during pregnancy. However, significantly lower platelet aggregation was 
noted postpartum after induction with ADP (Table 7). 
 
No statistically significant difference was found when platelet aggregation after 
activation with ADP in the two non-pregnant groups was compared. A slightly, but 
significantly, lower platelet aggregation after activation with AA, COL and TRAP in 
the postpartum group, compared with the non-pregnant, non-puerperal group, was 
found.  
 
Table 7. Comparison of platelet aggregation induced by different activators in  
women with known and unknown platelet count in the non-pregnant state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The t-test was used for comparison between groups.  
Calculation of CI for continuous variables is based on the assumption of normality. When variances 
are not equal (p<0.05) the SD is based on Satterthwaite´s approximation; otherwise, the SD is based 
on the pooled SDs. 
  
Activator of 
platelet aggregation 
 
 
 
Platelet aggregation 
Comparison 
between groups 
 
Platelet count  
known 
(n=45) 
Platelet count 
unknown 
(n=15) 
Mean (SD) 
Median (Min; Max) 
(Q1; Q3) 
n= 
Mean (SD) 
Median (Min; Max) 
(Q1; Q3) 
n= 
Mean difference 
(95% CI) 
p-value 
 
ADP 62.3 (21.1) 
61.0 (19.0; 118.0) 
(49.0; 76.0) 
n=45 
48.7 (15.2) 
46.0 (21.0; 78.0) 
(36.0; 60.0) 
n=15 
13.7  
(1.8; 25.5) 
p=0.024 
AA 82.2 (23.3) 
83.0 (15.0; 118.0) 
(69.0; 100.0) 
n=45 
71.3 (16.4) 
68.0 (47.0; 96.0) 
(63.0; 89.0) 
n=15 
10.8  
(-2.2; 23.9) 
p=0.10 
COL 66.2 (18.1) 
67.0 (31.0; 98.0) 
(55.5; 79.0) 
n=44 
57.5 (12.7) 
60.0 (33.0; 77.0) 
(49.0; 67.0) 
n=15 
8.69  
(-1.47; 18.86) 
p=0.092 
TRAP 94.2 (19.1) 
97.0 (38.0; 147.0) 
(85.0; 103.0) 
n=45 
84.0 (17.3) 
86.0 (55.0; 125.0) 
(79.0; 91.0) 
n=15 
10.2  
(-0.9; 21.4) 
p=0.072 
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Paper III 
 
Medical and obstetric history, medication, platelet aggregation, PC and demographic 
variables except smoking in the non-pregnant state for ASA- and placebo-treated 
women from the ASA-RCT were evenly distributed. Fewer placebo-treated women 
were smokers. The healthy controls had fewer previous complicated pregnancies and 
less previous illness, medication and smoking. The mean age was 32.3 (4.6), 32.0 
(4.2) and 29.3 (4.1) years, respectively, and there was no difference in BMI. Before 
pregnancy (non-pregnant state), AA-induced platelet aggregation was lower in the 
ASA group [mean 73.7 (21.3) U], compared with the placebo-treated group [mean 
79.9 (23.0) U] and healthy controls [mean 80.6 (20.6) U] 8-12 weeks postpartum 
(non-pregnant state) (p<0.001).  
 
Women in the ASA-RCT had normal values for Hb, PC, PC(INR) and APTT before 
pregnancy, except one woman in the placebo group, who had PC 76 and 66 x109/L 
at the two sampling time-points during pregnancy. As expected, Hb, PC, PC(INR) 
and APTT were significantly lower at gw 20, compared with the non-pregnant state. 
Women in the healthy control group had PC above 100 x 109/L during pregnancy 
and postpartum. 
 
No differences were observed in AA-induced platelet aggregation at any time-point 
during pregnancy and postpartum, when the placebo-treated women with 
unexplained RPL were compared with healthy women with normal pregnancy (Fig. 
13). Significantly decreased AA-induced platelet aggregation was found in ASA- 
treated women in gw 13, 30 and 36 compared with the pre-pregnant state (Fig. 13). 
The decrease diminished gradually during pregnancy but was still >50% for 74% of 
the ASA-treated women at the end of the third trimester. The ASA-treated women 
had significantly lower AA-induced platelet aggregation at every time-point during 
pregnancy, compared with both placebo-treated women and healthy women with 
normal pregnancy. 
 
Full response to ASA was found in 68 of 103 (66%) women, who had ASPI tests 
(AA-induced platelet aggregation) <30 U at all three time-points during pregnancy. 
Two women (1.9%) were found to be non-responders (ASPI >30 U at every 
sampling). The remaining 33 women (32.1%) with varying platelet aggregation 
(ASPI values more or less than 30 U) at the different time-points during pregnancy 
were regarded as partial responders. Individual results during ASA treatment in 
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women with normal AA-induced platelet aggregation and low AA-induced platelet 
aggregation, respectively, are shown in figures 14 and 15. 
 
The placebo-treated women from the ASA-RCT did not differ in AA-induced 
platelet aggregation at any time-point during pregnancy, compared with before 
pregnancy. A small, but statistically significant, decrease in platelet aggregation was 
observed for the healthy controls with normal pregnancies, when gw 8-15 and 37-40 
were compared with the non-pregnant state. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. Comparison of platelet aggregation, measured with the ASPI test (Units),  
in women with recurrent pregnancy loss treated with ASA or placebo, as well as in  
healthy women with normal pregnancy. 
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Fig. 14. Arachidonic acid (AA) induced platelet aggregation in pregnant women with unexplained 
recurrent pregnancy loss and normal AA-induced platelet aggregation before pregnancy. Each line 
indicates an individual woman during treatment with ASA or placebo or no treatment, grouped 
according to inhibition pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Arachidonic acid (AA) induced platelet aggregation in pregnant women with unexplained 
recurrent pregnancy loss and low AA-induced platelet aggregation before pregnancy. Each line 
indicates an individual woman during treatment with ASA or placebo or no treatment, grouped 
according to inhibition pattern. 
 
 
 
Before pregnancy Before pregnancy Before pregnancy
Gestational week 13      30        36                           13         30        36                             13       30        36 
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At the end of the third trimester, 74% of ASA-treated women demonstrated a 50% 
decrease in AA-induced platelet aggregation, 80% had a 40% decrease and 81% had 
a 30% decrease (Fig. 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. Comparison of inhibition by ASA, expressed as different levels of decrease in arachidonic acid-
induced platelet aggregation, in women with recurrent pregnancy loss treated with ASA or placebo 
and healthy women with normal pregnancy. 
 
 
Paper IV 
 
A total of 495 women were included in this study. Of the 619 women assessed for 
the ASA-RCT, 475 were included. Twenty women who met the inclusion criteria for 
the ASA-RCT and who had undergone the same tests and examinations as in the 
RCT, were also included in this study. All participants had complete sets of thyroid 
blood samples and documented pregnancy outcomes (Fig. 8). 
 
The participants in this study had very similar demographic characteristics as the 
women in the ASA-RCT: mean age 32.5 years, mean BMI 24.0 kg/m2 and three to 
seven consecutive unexplained first-trimester miscarriages in their history. Previous 
thyroid disease was reported for 32 women (8.6%), but they had all been euthyroid, 
with ongoing levothyroxine treatment, during the periods in which their miscarriages 
had occurred.  
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Among the 495 women, 78% had a live birth and 20% had a first-trimester 
miscarriage, of which 13 occurred in biochemical pregnancies.   
 
Baseline differences according to TPO status were found regarding the number of 
previous miscarriages, previous thyroid disease and ongoing treatment with 
levothyroxine. Baseline differences according to TSH levels were found in the 
number of previous live births and ongoing treatment with levothyroxine, 
antihistamines or anti-depressants.  
 
In the univariable regression analyses, three variables were potentially predictive of 
a new miscarriage: number of previous miscarriages, age and presence of TPO-ab.  
Women with positive TPO-ab had a higher miscarriage rate than TPO-ab-negative 
women. The RR for a new first-trimester miscarriage was 1.47 (95%CI 1.02 to 2.11), 
while the adjusted RR was 1.40 (95%CI 0.99 to 2.00). Miscarriage rates were similar 
in women with TSH in the upper and lower normal ranges, respectively. The RR was 
0.93 (95% CI 0.46 to 1.85) and no confounding factor was applicable. Analysis after 
exclusion of patients with a biochemical pregnancy as an outcome did not 
significantly affect the results.  
 
In a stepwise logistic regression analysis, the number of previous miscarriages was 
the most important risk factor for a new miscarriage, followed by age and presence 
of TPO-ab.  
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Discussion 
 
 
In our studies, we found that treatment with 75 mg ASA daily did not improve the 
outcome with regard to a new miscarriage or a live birth in women with unexplained 
RPL (Paper I). A minor decrease was found in platelet aggregation, after induction 
by AA, ADP and TRAP. No difference was seen regarding to COL. A minor increase 
in aggregation after ADP activation was found as pregnancy continued. AA-induced 
platelet aggregation in both the non-pregnant state and during pregnancy is similar 
in women with and without RPL (Paper III). ASA inhibition of AA-induced platelet 
aggregation is strong but decreases as pregnancy progresses. TPO-ab may be a risk 
factor for a new miscarriage, but this issue requires further evaluation (Paper IV). 
Finally, an important finding is that the LBR was high in all study groups. 
 
 
Paper I 
 
Variations in RPL populations and interventions make comparisons between studies 
problematic. Populations may vary depending on the definition of RPL, i.e. at least 
two or at least three previous miscarriages, gestational age, consecutive or not, or 
within the same relationship or not.  Our decision to include couples with three or 
more unexplained miscarriages was based on the contemporary definition when the 
RCT was planned.  We found that about 15% had a new miscarriage during the 
course of the study, with or without active treatment.  This rate is similar to the results 
of other RCTs (Dolitzky et al., 2006; Tulppala et al., 1997), but considerably lower 
than that found in observational studies (Brigham et al., 1999; Clifford et al., 1997).  
Thrombosis in decidual vessels is believed to be a possible cause of recurrent 
miscarriage (Rai, 2003; Carp et al., 2004; Dolitzky et al., 2006; Badawy et al., 2008). 
Pregnancy itself is a hypercoagulable state (Dolitzky et al., 2006; Rai et al., 2000) 
and the levels of procoagulant microparticles are higher in women with RPL than in 
controls (Laude et al., 2001; Stirling et al., 1984).  
 
In the early weeks of pregnancy, intermediate trophoblasts invade the decidual 
segments of the spiral arteries, causing physiological structural modifications. 
Insufficiency of the transformed arteries may give rise to early pregnancy loss 
(Dogan Gun et al., 2006). Intermediate trophoblastic cells are important for 
implantation and establishment of the utero-placental circulation (Wan et al., 1992; 
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Gerdsel et al., 2002). Intervillous circulation of maternal blood is likely to be 
established progressively between gws 8 and 12 (Valentin et al., 1996; Jaffe et al., 
1997; Carbillon et al., 2001). 
 
From the histopathological standpoint, recurrent early pregnancy loss is ascribed to 
lesions in the placental bed, including fibrinoid necrosis and acute atherosis of the 
spiral arteries (Rushton, 1988; Dogan Gun et al., 2006). These findings are of 
considerable interest, as they are related to preeclampsia and intrauterine growth 
retardation later in pregnancy, but they are also interesting in relation to spontaneous 
abortion in early pregnancy. Examination of freshly aborted fetuses and placentas 
revealed uteroplacental ischemia and retroplacental hemorrhage in almost one fifth 
of cases (Rushton, 1988). Comparison of vessels in elective abortion decidua and 
those in spontaneous abortion decidua revealed many more converted spiral arteries 
in the former than in the latter (Dogan Gun et al., 2006). This author concluded that 
spontaneous abortion was associated with a significantly increased incidence of 
inadequate placentation, particularly reduction or absence of trophoblastic invasion 
and defect transformation of the spiral arteries (Dogan Gun et al., 2006). 
 
According to our results reported in Papers I and III, we did not find any support for 
the hypothesis of hypercoagulability, expressed as increased AA-induced platelet 
aggregation, as a cause of unexplained recurrent first-trimester miscarriage. 
 
In our ASA-RCT (Paper I), treatment with ASA or placebo started after detection of 
fetal heartbeat by ultrasound, at about seven gestational weeks. Thus we cannot draw 
any conclusions about pregnancy outcome if treatment had started before ovulation 
or at positive pregnancy test. The findings of Rushton and Dogan Gun indicate that 
earlier start of treatment may result in a higher LBR than we found. 
 
Most studies compare ASA with other drugs, alone or in combination. There were, 
however, no previous robust studies comparing ASA alone with placebo in women 
with three or more consecutive unexplained first-trimester miscarriages. One small 
underpowered RCT, in which ASA 50 mg was compared with placebo, showed a 
similar LBR as our study (Tulppala et al., 1997). In a large observational study with 
three or more consecutive first-trimester miscarriages, 75 mg ASA was compared 
with no treatment. LBRs were 68.4% and 63.5%, respectively (Rai R et al., 2000). 
A comparison of treatment with either 40 mg enoxaparin or 100 mg ASA in women 
with three or more consecutive first-trimester miscarriages revealed LBRs of 81.5% 
and 84.0%, respectively (Dolitzky et al., 2006). Although these three studies 
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included an intervention with ASA treatment, they differed as to the time-point for 
starting treatment.  Treatment started earlier in two of these studies - within five 
weeks of amenorrhea (Rai et al., 2000) and after positive pregnancy test (Tulppala 
et al., 1997), respectively - while the third had a similar starting point, i.e. at gw 6-7 
(Dolitzky et al., 2006), as in our study. 
 
We chose to include only first-trimester miscarriages, since etiologies for second- 
trimester miscarriage are different, e.g. uterine infection and cervical incompetence. 
Four of the seven second-trimester miscarriages in our study were associated with a 
verified intrauterine infection. 
 
We considered it important to determine blood levels of ASA during treatment in 
order to verify compliance. In order to find an appropriate method for this,  15 
volunteers from the staff at the Department of Obstetrics and Gynecology at Södra 
Älvsborgs Hospital, healthy and without conflicting medication, had been recruited 
and given either 75 mg ASA for two weeks or no treatment. However, it was not 
possible for the hospital laboratory to detect any difference between the groups 
related to this low ASA dose. We subsequently found that AA-induced platelet 
aggregation (ASPI test), analyzed with the Multiplate analyzer, was an appropriate 
method for checking compliance.  
 
In the ASA-RCT, we found a marked decrease in AA-induced platelet aggregation 
in ASA-treated women, while no corresponding decrease in the placebo-treated 
group was demonstrated. This finding indicates very good adherence to treatment, 
but contradicts the hypothesis that platelet aggregation induced by AA is involved in 
first-trimester RPL after verification of a viable fetus. However, we do not know 
what would have happened if the ASA treatment would have been started at 
ovulation or before conception. Furthermore, we cannot rule out that platelet 
aggregation induced by other activators, such as COL, ADP or TRAP, might have 
affected the RPL rate.  
 
In our study, as well as in others, there was a high LBR, which indicates a good 
prognosis for this group. The extensive follow-up program, applied to both study 
groups, may have been a contributory factor to the high LBR in this study. Many 
authors emphasize that women with unexplained first-trimester RPL have a very 
good prognosis (75-86%) for a successful pregnancy if provided with psychological 
support and high access to caregivers, even in the absence of pharmacological 
intervention (Clifford et al., 1997; Brigham et al., 1999; Rai et al., 2006; Badawy et 
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al., 2008; Morley et al., 2013; Kutteh et al., 2014; Musters et al., 2013). This concurs 
with our perception that our study participants had a high rate of successful 
pregnancy, and that they also emphasized the importance of the follow-up program 
and the possibility to easily contact the PI. However, the effect of “tender loving 
care” has not as yet been properly investigated in a RCT (Rasmark Roepke et al., 
2018). 
 
 
Paper II 
 
There were a few small previous studies describing platelet aggregation during 
normal pregnancy (Burke et al., 2013; Louden et al., 1990). We sought a suitable 
method for determining platelet aggregation in order to study differences between 
healthy women and women with RPL regarding platelet aggregation, ASA effect and 
treatment compliance. We found that multiple electrode impedance aggregometry 
was one of the most applied methods in other study populations undergoing ASA 
treatment (Jambor et al., 2009; Oscarsson et al., 2011). However, we also discovered 
that there was a lack of robust experience of the method in connection with 
pregnancy.  
 
Therefore, we undertook this study in order to gain knowledge of platelet aggregation 
during normal pregnancy in healthy women. Determining platelet aggregation 
longitudinally during normal pregnancy in healthy women was also a prerequisite to 
evaluate whether platelet aggregation is increased in women with RPL. 
 
In this study, platelet aggregation was measured longitudinally after induction by 
AA, ADP, COL and TRAP, respectively. We found a minor decrease in platelet 
aggregation, after activation by AA, ADP and TRAP, compared with postpartum. 
No difference was seen regarding COL. A minor increase in aggregation after ADP 
activation was found as pregnancy continued. We believe that the minor changes in 
platelet aggregation that we found probably lack clinical significance under normal 
conditions. 
 
As the women in this study were recruited in early pregnancy, it was impossible to 
obtain non-pregnant platelet aggregation results before the current pregnancy. 
Previous studies have shown normalized platelet function within 6 to 12 weeks 
postpartum (Norris et al., 1994; Louden et al., 1990). Therefore, we chose three 
months postpartum as the non-pregnant state for analysis. In our study a small but 
69 
 
statistically significant difference was noted when the non-pregnant, puerperal 
women were compared with non-pregnant, non-puerperal, fertile-age, healthy 
women. This could be due to a residual effect of pregnancy, different populations or 
differences in handling the method.  
 
Some older previous studies have shown increased platelet aggregation induced by 
AA, ADP and COL in normal pregnancy (Morrison et al., 1985; Leuschen et al., 
1986). In a small longitudinal study by Louden (1990), eight healthy pregnant 
women with normal pregnancy and delivery were compared with 12 healthy non-
pregnant women regarding platelet aggregation, induced by AA, ADP and COL and 
analyzed with the Ultra-Flo 100 system. No significant changes after ADP and COL 
induction were observed, but after AA induction, there was a significant increase in 
platelet aggregation at gw 32, compared with the first trimester. Platelets seemed to 
be more reactive to AA stimulation in normal pregnancy, beginning from gw 16 
(Louden et al., 1990). In a longitudinal study during pregnancy including 36 non-
smoking pregnant women and 30 healthy non-pregnant controls, blood samples for 
platelet aggregation analysis were drawn (Burke et al., 2013). They were analyzed 
with light transmission aggregometry after induction by AA, ADP, COL and TRAP. 
The main findings were significantly reduced platelet reactivity after COL induction 
in the first trimester and significantly increased platelet reactivity after AA induction 
in the second and third trimesters. 
 
 
Paper III 
 
No difference was found in AA-induced platelet aggregation when women with at 
least three unexplained consecutive first-trimester miscarriages were compared with 
healthy women with uncomplicated pregnancy and normal delivery at term. 
Increased platelet aggregation has been suggested by previous authors to be a causal 
factor of recurrent miscarriage in early pregnancy (Flood et al., 2010). The absence 
of any difference in AA-induced platelet aggregation between the healthy controls 
and women with recurrent miscarriages may indicate that AA-induced platelet 
aggregation is not a cause of recurrent first-trimester miscarriage.  
 
Treatment with 75 mg ASA daily during pregnancy from gw 7 to gw 36 resulted in 
markedly lower platelet aggregation, but the degree of inhibition decreased as 
pregnancy progressed. However, AA-induced platelet aggregation remained reduced 
by more than 50% during the entire pregnancy in the majority of ASA-treated 
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women. This has not been previously reported. Our study suggests that the ASA dose 
should be increased during the third trimester in order to yield unaltered effect 
throughout pregnancy. The ongoing debate about prophylactic doses of ASA for 
prevention of preeclampsia and other placenta-mediated complications necessitates 
further studies, including of platelet aggregation. It is important to understand the 
mechanism through which ASA exerts its effects in these conditions in order to 
determine the right dose.  A low dose of ASA, 75 mg daily, seems to be as effective 
as a high dose, i.e. 325 mg daily (Patel et al., 2007). The most effective ASA dose in 
preventing cardiovascular events seems to be 75-150 mg, which has similar efficacy 
as doses up to 1500 mg ASA daily (Mansour et al., 2009). A systematic review and 
meta-analysis of the outcomes moderate and severe preeclampsia and intrauterine 
growth retardation (Roberge et al., 2016) found that treatment with 75-150 mg ASA 
daily was associated with a reduction of all three studied outcomes. Individualized 
dosage of ASA after platelet function testing has been found to be effective in 
preventing preeclampsia in high-risk women (Rey et al., 2011).  In our study, we 
found increased platelet aggregation as pregnancy progressed during treatment with 
75 mg ASA. In most RPL studies, 50-100 mg of ASA has been used and no effect 
on LBR has been demonstrated based on dosage (Kaandorp et al., 2009; Tulppala et 
al., 1997; de Jong et al., 2014). 
 
Platelet aggregation was analyzed by multiple electrode impedance aggregometry 
after induction by AA (ASPI test). We found full response to ASA (ASPI <30 U at 
all testing time-points during pregnancy) in about two-thirds and varying response 
in one-third of the pregnant women during pregnancy. The Multiplate method is most 
suitable for detection of changes in platelet aggregation within an individual during 
drug treatment, as there is wide inter-individual variation.   
 
The definition of non-response is problematic due to different populations, study 
designs and test methods. A generally accepted definition based on valid diagnostic 
criteria has not yet been established (Zimmermann et al., 2008). There is a laboratory 
definition of resistance to ASA therapy, i.e. failure of ASA to inhibit TXA2 
production,  estimated to affect 24-28% (Zimmermann et al., 2008; Patel et al., 2007) 
There is also a clinical definition, i.e. the occurrence of thrombotic cardiovascular 
ischemic events despite regular ASA therapy, according to some authors (Patel et al., 
2007).  
 
Only two women (1.9%) were non-responders to ASA (all ASPI ≥30 U during 
pregnancy). This incidence of non-responders is much lower than previously 
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reported among obstetric populations (Navaratnam et al., 2016; Caron et al., 2009). 
We defined women with one ASPI value ≥30 U at any testing time-point during 
pregnancy, in whom the levels at the other time-points were below 30 U, as partial 
responders; this applied to 32.1%. We have not seen partial responders defined in 
any other study. Together, our non-responders and partial responders constituted 
34%. If this combined group had been redefined as non-responders, the prevalence 
would be in line with previously reported prevalences of 29-39% non-responsiveness 
in obstetric populations (Navaratnam et al., 2016). In another cohort of 87 pregnant 
women, 25 were non-responders to 81 mg ASA daily (Caron et al., 2009). After 
increasing the dose to 162 mg, only eight women were still non-responders, 
indicating that the lack of response can be overcome with higher doses in most 
individuals. 
 
 
Paper IV 
 
Our cohort was selected to comprise only patients with normal thyroid hormone 
levels, including those with normal thyroid function as well as those taking 
levothyroxine, who were euthyroid during their miscarriage history. 
 
We found that women with positive TPO-ab had a higher miscarriage rate than 
women lacking TPO-ab. This concurs with some previous studies (Negro et al., 
2005; Stagnaro-Green et al., 2011), while others have reported no such association 
in women with RPL (Pratt et al., 1993; Esplin et al., 1998; Rushworth et al., 2000; 
Yan et al., 2012).  
 
When TSH levels in the upper and lower normal ranges were compared in our study, 
the miscarriage rates were similar, 21.1% and 21.4%, respectively. TSH in the upper 
normal range was not thus associated with an increased risk of pregnancy loss. 
According to the literature, TSH levels in the upper normal range are often referred 
to as subclinical hypothyroidism, which is formally defined as elevated TSH in 
combination with normal free T4. Conflicting results regarding the risk for a new 
miscarriage related to subclinical hypothyroidism in RPL patients have been reported 
(van den Boogaard et al., 2011; van Dijk et al., 2016).  
 
We identified number of previous miscarriages, age and TPO-ab in a risk factor 
model. Very few previous studies have investigated these risk factors using a 
multivariable technique. Two authors report correlations between miscarriage and 
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higher age and the presence of TPO-ab. Higher age is an independent risk factor for 
miscarriage and most TPO-ab-positive women are older than women without TPO-
ab (Ashrafi et al., 2007; Roberts et al., 2000). 
 
Women with biochemical pregnancy losses were included in the study population; 
exclusion of these women did not significantly affect the results. In most studies of 
recurrent (≥three) first-trimester miscarriages focusing on elevated TSH and TPO-
ab, biochemical pregnancy has not been discussed. Some studies have mentioned, 
and included, biochemical pregnancies but the results have not been reported 
separately (Liu et al., 2014; Kaur et al., 2016; Vissenberg et al., 2016). Only one 
study explicitly stated that biochemical pregnancies were excluded (van Dijk et al., 
2016). 
 
TPO-ab was chosen as a biomarker of thyroid autoimmunity as it is the most common 
thyroid antibody (Frölich et al., 2017). TPO-ab as a risk factor for a new first-
trimester miscarriage in women with RPL is under debate, as illustrated by varying 
reported results. In our study, positive TPO-ab, but not TSH in the upper normal 
range, affected the risk of a new miscarriage. It may be the thyroid autoimmunity per 
se, rather than impaired thyroid function, that causes the miscarriage. Normal thyroid 
function is required for fetal-placental development (Vissenberg et al., 2015), and if 
thyroid gland reserve capacity is reduced by autoimmune disease, it can manifest in 
early pregnancy as a miscarriage.  
 
 
Strengths 
 
The strength of this thesis is that it is based mainly on a large RCT with a complete 
follow-up and total adherence to the study protocol. By applying the definition of at 
least three, and not two, consecutive unexplained first-trimester miscarriages, 
“random miscarriages” were avoided. Thus, the study population was more likely to 
have been a “true” RPL population. Measurement of platelet aggregation to check 
compliance added important information. The low prevalence of smokers in the 
study population was advantageous, since smoking has been associated with non-
responsiveness to ASA. 
 
We are not aware of any previous large study that has presented results on platelet 
aggregation, determined by impedance aggregometry and induced by four different 
agonists, longitudinally during normal pregnancies in healthy women (Paper II). Nor 
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were there, to our knowledge, published results of studies undertaking longitudinal 
comparison during pregnancy of women with and without recurrent unexplained 
first-trimester miscarriage, or of studies investigating the effect of ASA treatment 
during pregnancy among women with RPL (Paper III). 
 
The population screened for eligibility for the ASA-RCT was well documented, 
which enabled conduction of the post hoc studies. 
 
 
Limitations 
 
Some limitations in the design of the RCT can be noted. The adverse effects were 
reported in response to an open question and not according to a pre-specified report 
form at the prenatal visits. Other limitations refer to the planning of laboratory 
testing. It would have been valuable to have analyzed hCG in early pregnancy for 
correlation with TSH, as well as to have repeated the thyroid hormone tests during 
pregnancy. Moreover, the ASPI test was not performed until gw 13, precluding any 
information on inhibition of platelet aggregation in women who miscarried in the 
first trimester. 
 
In the cohort of healthy women with normal pregnancy, the loss to follow-up three 
months postpartum was high but anticipated. Furthermore, the importance of missing 
PCs in some women at certain time-points during pregnancy had to be investigated, 
since platelet aggregation is dependent on PC. However, sensitivity analysis revealed 
that there was no difference in platelet aggregation in women with and without 
available PC.  
 
 
Clinical implications 
 
A very strong recommendation, based on high-quality evidence from the ASA-RCT, 
is that women with a history of RPL not be treated with ASA, beginning in early 
pregnancy when a fetal heartbeat is detected, with the intention of reducing the risk 
for a new miscarriage.  Whether ASA treatment initiated at ovulation or on the date 
of a missed period would affect the subsequent miscarriage risk is still unknown. 
Thus, this treatment should only be considered in the context of a RCT.   
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Our results may have implications on dosage of ASA during pregnancy, when 
prescribed on other indications such as prevention of preeclampsia. In order to 
maintain unaltered inhibition of platelet aggregation throughout pregnancy, the dose 
should be increased at least during the third trimester.  
 
The Multiplate method might have a place in monitoring platelet aggregation during 
drug treatment in individual pregnant patients, as is already the case in non-pregnant 
patients. The method is not suitable for determination of minor intra-individual 
changes.  
 
The presence of TPO-ab as a potential risk factor for a new miscarriage should be 
recognized when women and their partners seek help for RPL. 
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Conclusions 
 
 
 Treatment with 75 mg ASA, initiated after detection of a viable pregnancy, did 
not prevent a new miscarriage in women with at least three previous first-
trimester unexplained miscarriages in the current relationship. This population 
had a very good prognosis for a subsequent live birth, both with and without ASA 
treatment.  
 
 Platelet aggregation induced by AA, ADP, and TRAP, and longitudinally 
measured by multiple electrode impedance aggregometry, underwent minor 
changes during pregnancy, compared with the non-pregnant state. Platelet 
aggregation after COL activation was unchanged. These changes probably lack 
clinical significance under normal conditions.  
 
 During pregnancy and in the non-pregnant state, women with recurrent 
unexplained miscarriages seem to have the same degree of AA-induced platelet 
aggregation as healthy women with normal pregnancies. Platelet aggregation 
induced by AA is not a plausible causal factor for recurrent unexplained first-
trimester miscarriage.  
 
 AA-induced platelet aggregation was inhibited, and remained reduced by at least 
50% throughout pregnancy, in the majority of ASA-treated women. The 
reduction was less pronounced later in pregnancy. This may indicate a need to 
increase prophylactic low dose ASA as pregnancy progresses in order to achieve 
unaltered effect throughout pregnancy.  
 
 Euthyroid, TPO-ab-positive women with a history of RPL may have an increased 
risk for a new miscarriage, compared with women without TPO-ab. Age and 
number of previous miscarriages are strong risk factors for a new miscarriage. 
The risk of a new miscarriage was not influenced by TSH levels if they were 
within the normal range.  
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Future perspectives 
 
 
Women with unexplained first-trimester RPL are a vulnerable group, for whom no 
established treatment is available. Women seeking help for RPL are likely to accept 
experimental treatment, but all suggested treatments should only be given in the 
context of a RCT at present. For every suggested treatment, there is an underlying 
mechanism theory that needs to be tested.  
 
This thesis focuses on ASA treatment and the underlying suggested explanation that 
inhibition of platelet aggregation would reduce the risk of a new miscarriage. A 
similar LBR, regardless of treatment allocation, was demonstrated. However, it 
cannot be ruled out that ASA initiated before or at implantation might have a 
beneficial effect on the risk of a new miscarriage. To test that hypothesis, a placebo-
controlled trial evaluating low-dose ASA initiated before ovulation or during the 
luteal phase is required.  
 
The LBRs were fairly high (85%) in both randomization groups. Both groups 
attended an extended follow-up program, which raises the question of the impact of 
the follow-up on the overall results. The concept of ‘tender loving care’ has been 
discussed for more than half a century, but has never been tested with a randomized 
design.  
 
We found major inter-individual variations when healthy women with normal 
pregnancies were examined with impedance aggregometry for analysis of platelet 
aggregation, induced by AA, ADP, COL and TRAP. Thus, a larger pregnant 
population is needed to establish a reference range for the method, if it is to be used 
clinically in pregnant women treated with platelet aggregation inhibitors. 
 
The inhibition of platelet aggregation by ASA treatment decreased as pregnancy 
progressed. This finding has not been previously reported and thus requires 
verification. The clinical implication is to consider increasing the ASA dose as 
pregnancy progresses, when it is given to prevent obstetric complications such as 
preeclampsia. The magnitude of the dose increase must be studied in a clinical setting 
before any recommendation can be made.  
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The effect of TPO-ab and subclinical hypothyroidism on miscarriage risk among 
women with RPL must be studied further. The finding that TPO-ab are a potential 
risk factor must be evaluated in a larger population, preferably with a prospective 
cohort design, and the protocol should include repeated thyroid tests as well as 
analysis of hCG.  Loss of biochemical pregnancies also merits attention.  
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